CN114805361A - Amino-substituted aromatic heterocyclic pyrazole compounds, preparation method and application - Google Patents
Amino-substituted aromatic heterocyclic pyrazole compounds, preparation method and application Download PDFInfo
- Publication number
- CN114805361A CN114805361A CN202210051634.4A CN202210051634A CN114805361A CN 114805361 A CN114805361 A CN 114805361A CN 202210051634 A CN202210051634 A CN 202210051634A CN 114805361 A CN114805361 A CN 114805361A
- Authority
- CN
- China
- Prior art keywords
- substituted
- membered
- unsubstituted
- alkyl
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Amino-substituted aromatic heterocyclic pyrazole compounds Chemical class 0.000 title claims abstract description 132
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 35
- 239000000651 prodrug Substances 0.000 claims abstract description 29
- 229940002612 prodrug Drugs 0.000 claims abstract description 29
- 239000012453 solvate Substances 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims description 135
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 46
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 39
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 32
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 229910052736 halogen Inorganic materials 0.000 claims description 29
- 150000002367 halogens Chemical class 0.000 claims description 29
- 229910052757 nitrogen Inorganic materials 0.000 claims description 27
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 20
- 229910052805 deuterium Inorganic materials 0.000 claims description 20
- 125000001188 haloalkyl group Chemical group 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 claims description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 18
- 108091007914 CDKs Proteins 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 14
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 13
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 12
- 125000004122 cyclic group Chemical group 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 10
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 10
- 125000002950 monocyclic group Chemical group 0.000 claims description 9
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 6
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 6
- 206010040070 Septic Shock Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000000304 alkynyl group Chemical group 0.000 claims description 5
- 125000003368 amide group Chemical group 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 229910052698 phosphorus Inorganic materials 0.000 claims description 5
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 4
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 4
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 claims description 4
- 125000005103 alkyl silyl group Chemical group 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000005179 haloacetyl group Chemical group 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 125000003003 spiro group Chemical group 0.000 claims description 4
- 229940124530 sulfonamide Drugs 0.000 claims description 4
- 150000003456 sulfonamides Chemical class 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 2
- FEWLNYSYJNLUOO-UHFFFAOYSA-N 1-Piperidinecarboxaldehyde Chemical compound O=CN1CCCCC1 FEWLNYSYJNLUOO-UHFFFAOYSA-N 0.000 claims description 2
- YVTPINJIEGFACL-UHFFFAOYSA-N 1-piperidin-1-yloxypiperidine Chemical compound C1CCCCN1ON1CCCCC1 YVTPINJIEGFACL-UHFFFAOYSA-N 0.000 claims description 2
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 claims description 2
- 208000011594 Autoinflammatory disease Diseases 0.000 claims description 2
- 206010060999 Benign neoplasm Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010014824 Endotoxic shock Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 2
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 125000002837 carbocyclic group Chemical group 0.000 claims description 2
- OCDXZFSOHJRGIL-UHFFFAOYSA-N cyclohexyloxycyclohexane Chemical compound C1CCCCC1OC1CCCCC1 OCDXZFSOHJRGIL-UHFFFAOYSA-N 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- HACFQMOMUFJPQH-UHFFFAOYSA-N piperidin-2-ylidenemethanamine Chemical compound NC=C1CCCCN1 HACFQMOMUFJPQH-UHFFFAOYSA-N 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 106
- 239000000543 intermediate Substances 0.000 description 88
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 87
- 238000006243 chemical reaction Methods 0.000 description 72
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 64
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 62
- 230000002829 reductive effect Effects 0.000 description 52
- 239000007787 solid Substances 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 41
- 239000000243 solution Substances 0.000 description 37
- 239000012043 crude product Substances 0.000 description 36
- 239000012074 organic phase Substances 0.000 description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 36
- 238000000034 method Methods 0.000 description 33
- 239000000203 mixture Substances 0.000 description 33
- 239000011541 reaction mixture Substances 0.000 description 30
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 22
- 238000005481 NMR spectroscopy Methods 0.000 description 22
- 239000013067 intermediate product Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 15
- 239000000706 filtrate Substances 0.000 description 14
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 238000010898 silica gel chromatography Methods 0.000 description 13
- 239000002253 acid Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 12
- 238000000926 separation method Methods 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 10
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 239000003480 eluent Substances 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 238000004809 thin layer chromatography Methods 0.000 description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 150000001735 carboxylic acids Chemical class 0.000 description 7
- 150000001805 chlorine compounds Chemical class 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 7
- 239000001301 oxygen Chemical group 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000011593 sulfur Chemical group 0.000 description 7
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 5
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 5
- ITGIYLMMAABTHC-ONEGZZNKSA-N (e)-4-(dimethylazaniumyl)but-2-enoate Chemical compound CN(C)C\C=C\C(O)=O ITGIYLMMAABTHC-ONEGZZNKSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000022131 cell cycle Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 101710106276 Cyclin-dependent kinase 7 Proteins 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 230000005311 nuclear magnetism Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- FWIROFMBWVMWLB-UHFFFAOYSA-N 1-bromo-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(Br)=C1 FWIROFMBWVMWLB-UHFFFAOYSA-N 0.000 description 2
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical compound C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 2
- IEUKCNPRRGOGDG-UHFFFAOYSA-N 5-bromo-2,3-dihydro-1h-inden-1-amine Chemical compound BrC1=CC=C2C(N)CCC2=C1 IEUKCNPRRGOGDG-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010025461 Cyclin-Dependent Kinase 9 Proteins 0.000 description 2
- 102000013702 Cyclin-Dependent Kinase 9 Human genes 0.000 description 2
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 2
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 108010012271 Positive Transcriptional Elongation Factor B Proteins 0.000 description 2
- 102000019014 Positive Transcriptional Elongation Factor B Human genes 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 201000002313 intestinal cancer Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
- MJOSQKREOFDVAL-UHFFFAOYSA-N 1-hydroxypiperidine-2,2,3-triol Chemical compound OC1CCCN(O)C1(O)O MJOSQKREOFDVAL-UHFFFAOYSA-N 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N 10-undecenoic acid Chemical class OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- 125000005938 2,3-dihydro-1H-isoindolyl group Chemical group 0.000 description 1
- 125000005983 2,5-diazabicyclo[2.2.1]heptan-2-yl group Chemical group 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- PIMQWRZWLQKKBJ-SFHVURJKSA-N 2-[(2S)-1-[3-ethyl-7-[(1-oxido-3-pyridin-1-iumyl)methylamino]-5-pyrazolo[1,5-a]pyrimidinyl]-2-piperidinyl]ethanol Chemical compound C=1C(N2[C@@H](CCCC2)CCO)=NC2=C(CC)C=NN2C=1NCC1=CC=C[N+]([O-])=C1 PIMQWRZWLQKKBJ-SFHVURJKSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- GBNPVXZNWBWNEN-UHFFFAOYSA-N 2-chloro-4-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=NC(Cl)=C1 GBNPVXZNWBWNEN-UHFFFAOYSA-N 0.000 description 1
- LIEPVGBDUYKPLC-UHFFFAOYSA-N 2-chloro-4-nitropyridine Chemical compound [O-][N+](=O)C1=CC=NC(Cl)=C1 LIEPVGBDUYKPLC-UHFFFAOYSA-N 0.000 description 1
- LPBDZVNGCNTELM-UHFFFAOYSA-N 2-chloropyrimidin-4-amine Chemical compound NC1=CC=NC(Cl)=N1 LPBDZVNGCNTELM-UHFFFAOYSA-N 0.000 description 1
- HXVQPZSXXYOZMP-UHFFFAOYSA-N 2-chloropyrimidine-4-carbonitrile Chemical compound ClC1=NC=CC(C#N)=N1 HXVQPZSXXYOZMP-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical class NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical class OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 229940125888 CDK7 inhibitor Drugs 0.000 description 1
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 1
- 101100495324 Caenorhabditis elegans cdk-7 gene Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102100040428 Chitobiosyldiphosphodolichol beta-mannosyltransferase Human genes 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 102100036883 Cyclin-H Human genes 0.000 description 1
- 102100024109 Cyclin-T1 Human genes 0.000 description 1
- 108091016115 Cyclin-T1 Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 101000891557 Homo sapiens Chitobiosyldiphosphodolichol beta-mannosyltransferase Proteins 0.000 description 1
- 101000713120 Homo sapiens Cyclin-H Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 150000000994 L-ascorbates Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- HUXYBQXJVXOMKX-UHFFFAOYSA-N N-[6,6-dimethyl-5-[(1-methyl-4-piperidinyl)-oxomethyl]-1,4-dihydropyrrolo[3,4-c]pyrazol-3-yl]-3-methylbutanamide Chemical compound CC(C)CC(=O)NC1=NNC(C2(C)C)=C1CN2C(=O)C1CCN(C)CC1 HUXYBQXJVXOMKX-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 241001274216 Naso Species 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- NVSPJDGXKBDYIZ-UHFFFAOYSA-N [1,2,4]triazolo[4,3-a]pyrazine Chemical compound C1=NC=CN2C=NN=C21 NVSPJDGXKBDYIZ-UHFFFAOYSA-N 0.000 description 1
- AYSYSOQSKKDJJY-UHFFFAOYSA-N [1,2,4]triazolo[4,3-a]pyridine Chemical compound C1=CC=CN2C=NN=C21 AYSYSOQSKKDJJY-UHFFFAOYSA-N 0.000 description 1
- YRACHDVMKITFAZ-UHFFFAOYSA-N [1,2,4]triazolo[4,3-b]pyridazine Chemical compound C1=CC=NN2C=NN=C21 YRACHDVMKITFAZ-UHFFFAOYSA-N 0.000 description 1
- XUFCBCHWTOAVAA-UHFFFAOYSA-N [1,2,4]triazolo[4,3-c]pyrimidine Chemical compound C1=CN=CN2C=NN=C21 XUFCBCHWTOAVAA-UHFFFAOYSA-N 0.000 description 1
- AMOODQKTVNADCO-UHFFFAOYSA-N [dimethylphosphoryloxy(methyl)phosphoryl]methane Chemical compound CP(C)(=O)OP(C)(C)=O AMOODQKTVNADCO-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- PQKUBTPKFMSTRF-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CC(O)=O.CCOC(C)=O PQKUBTPKFMSTRF-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- JPNZKPRONVOMLL-UHFFFAOYSA-N azane;octadecanoic acid Chemical class [NH4+].CCCCCCCCCCCCCCCCCC([O-])=O JPNZKPRONVOMLL-UHFFFAOYSA-N 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 239000012964 benzotriazole Substances 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004623 carbolinyl group Chemical group 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000033366 cell cycle process Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid Chemical class OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000006880 cross-coupling reaction Methods 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- WHHGLZMJPXIBIX-UHFFFAOYSA-N decabromodiphenyl ether Chemical compound BrC1=C(Br)C(Br)=C(Br)C(Br)=C1OC1=C(Br)C(Br)=C(Br)C(Br)=C1Br WHHGLZMJPXIBIX-UHFFFAOYSA-N 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 125000005534 decanoate group Chemical class 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000012972 dimethylethanolamine Substances 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical class CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical class OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- MBVAHHOKMIRXLP-UHFFFAOYSA-N imidazo[1,2-a]pyrazine Chemical compound C1=CN=CC2=NC=CN21 MBVAHHOKMIRXLP-UHFFFAOYSA-N 0.000 description 1
- VTVRXITWWZGKHV-UHFFFAOYSA-N imidazo[1,2-b]pyridazine Chemical compound N1=CC=CC2=NC=CN21 VTVRXITWWZGKHV-UHFFFAOYSA-N 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 150000004701 malic acid derivatives Chemical class 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- RXZMYLDMFYNEIM-UHFFFAOYSA-N n,1,4,4-tetramethyl-8-[4-(4-methylpiperazin-1-yl)anilino]-5h-pyrazolo[4,3-h]quinazoline-3-carboxamide Chemical compound CNC(=O)C1=NN(C)C(C2=N3)=C1C(C)(C)CC2=CN=C3NC(C=C1)=CC=C1N1CCN(C)CC1 RXZMYLDMFYNEIM-UHFFFAOYSA-N 0.000 description 1
- MLACQEBQGUBHKX-UHFFFAOYSA-N n,n-dimethylpiperidin-1-amine Chemical compound CN(C)N1CCCCC1 MLACQEBQGUBHKX-UHFFFAOYSA-N 0.000 description 1
- OBJNFLYHUXWUPF-IZZDOVSWSA-N n-[3-[[5-chloro-4-(1h-indol-3-yl)pyrimidin-2-yl]amino]phenyl]-4-[[(e)-4-(dimethylamino)but-2-enoyl]amino]benzamide Chemical compound C1=CC(NC(=O)/C=C/CN(C)C)=CC=C1C(=O)NC1=CC=CC(NC=2N=C(C(Cl)=CN=2)C=2C3=CC=CC=C3NC=2)=C1 OBJNFLYHUXWUPF-IZZDOVSWSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 125000005060 octahydroindolyl group Chemical group N1(CCC2CCCCC12)* 0.000 description 1
- 125000005061 octahydroisoindolyl group Chemical group C1(NCC2CCCCC12)* 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical class CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Chemical group 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000031168 regulation of transcription elongation, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229950000055 seliciclib Drugs 0.000 description 1
- 150000003354 serine derivatives Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- 238000004808 supercritical fluid chromatography Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- RIFXIGDBUBXKEI-UHFFFAOYSA-N tert-butyl 3-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(=O)C1 RIFXIGDBUBXKEI-UHFFFAOYSA-N 0.000 description 1
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000005029 transcription elongation Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an amino-substituted aromatic heterocyclic pyrazole compound, a preparation method and application thereof, in particular to an amino-substituted aromatic heterocyclic pyrazole compound shown as a general formula I, or pharmaceutically acceptable salt thereof, or enantiomer, diastereoisomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof, a preparation method and a pharmaceutical application thereof, wherein the definition of each group is described in the specification.
Description
Technical Field
The invention belongs to the field of medicinal chemistry, and discloses an amino-substituted aromatic heterocyclic pyrazole compound with CDK kinase inhibitory activity, a medicinal composition and application thereof, in particular to a compound shown as a general formula I. The compounds of the present invention and pharmaceutical compositions comprising these compounds are useful in the prevention or treatment of related diseases, particularly those mediated by the aberrant activity of CDK kinases, particularly CDK7 kinase.
Background
Cell cycle abnormalities are a hallmark feature of cancer, and cyclin-dependent kinases (CDKs) are a class of serine/threonine kinases that play a central role in the cell cycle, leading to the initiation, progression, and termination of the cell cycle. The CDK family are important signal transduction molecules within cells, which form CDK-cyclin complexes with cyclins, and are involved in the growth, proliferation, dormancy and apoptosis of cells.
Over the past 20 years, drug development targeting CDK kinases for tumor therapy has received extensive attention, as flavopiridol (alvocidib), Seliciclib (CYC202), Dinaciclib (SCH727965) and micciclib (PHA-848125) have all entered into different stages of clinical studies. However, the clinical application is limited due to the fact that the CDK inhibitor discovered early has low inhibitory activity on each CDK family subtype, or lacks certain selectivity, or is poorly absorbed in vivo. In recent years, drug development in this area has again been a focus due to the discovery of selective inhibitors that either increase the selectivity of CDK inhibitors for each CDK family subtype or increase the inhibitory activity of CDK kinases, particularly targeting CDK 4/6.
Recent studies have found that CDK7 kinase of the CDK family has dual functions of regulating both kinase and transcription: 1) in the cytoplasm, CDK7 exists as a heterotrimeric complex and acts as an activated kinase (CAK) of CDK1/2, whereby phosphorylation of conserved residues in CDK1/2 by CDK7 is necessary for full catalysis of CDK activity and cell cycle progression; 2) in the nucleus, CDK7 forms the kinase core of the RNA polymerase (RNAP) II universal transcription factor complex and is responsible for phosphorylating the C-terminal domain (CTD) of rnapi, an essential step in gene transcription initiation. Two functions of CDK7, CAK and CTD phosphorylation, support key aspects of cell proliferation, cell cycle, and transcription. Research shows that CDK7 kinase has a very important effect on the regulation of triple negative breast cancer, and the inhibition of CDK7 kinase has a significant killing effect on the growth of triple negative breast cancer cells.
In addition, the CDK9 kinases of the CDK family play a role primarily in the regulation of transcriptional elongation without affecting cell cycle processes. The CDK9 inhibitor can prevent the phosphorylation of positive transcription elongation factor P-TEFb (positive transcription elongation factor b) on the RNA Poly-II C terminal region by degrading and inhibiting CDK9, inhibit transcription, and rapidly reduce the level of intracellular mRNA, thereby causing tumor cell apoptosis.
Although great progress has been made in the development of CDK kinase inhibitor drugs, some unsolved problems such as drug resistance of existing CDK kinase inhibitor drugs, subtype selectivity to CDK kinase family targets and the like exist, so that research and development of novel CDK kinase inhibitors with high efficiency, low toxicity, resistance and clinical application value, such as specific CDK7 kinase inhibitors, are urgently needed in the art.
Disclosure of Invention
One of the technical problems to be solved by the present invention is to provide a novel CDK7 inhibitor for preparing tumor treatment drugs.
The scheme for solving the technical problems is as follows:
an amino-substituted aromatic heterocyclic pyrazole compound shown as a general formula I, or pharmaceutically acceptable salt thereof, or enantiomer, diastereoisomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof,
in the formula:
w is selected from CR w Or N; rw is independently selected from H, halogen, cyano, C1-C6 alkyl or haloalkyl;
R 1 independently selected from C1-C10 alkyl or haloalkyl, 3-10 membered cycloalkyl or heterocycloalkyl, C1-C10 alkoxy or haloalkoxy, 3-10 membered cycloalkyl ether or heterocycloalkyl ether, C1-C10 alkyl or haloalkyl substituted amino, 3-10 membered cycloalkyl or heterocycloalkyl substituted amino(ii) a And the above alkyl, cycloalkyl, heterocycloalkyl may be substituted with one or several substituents selected from the group consisting of: halogen, deuterium, hydroxyl, substituted or unsubstituted amino, C1-C6 alkyl, hydroxyl-substituted C1-C6 alkyl, amino-substituted C1-C6 alkyl, C1-C6 alkoxy, 3-10 membered cycloalkyl or heterocycloalkyl-substituted C1-C6 alkyl;
R 2 independently selected from C1-C10 alkyl or haloalkyl, 3-10 membered cycloalkyl or heterocycloalkyl;
ra is selected from hydrogen, deuterium, halogen, C1-C6 alkyl or haloalkyl, 3-10 membered cycloalkyl or heterocycloalkyl;
rb, Rc, Rd, Re are each independently selected from hydrogen, deuterium, halogen, C1-C6 alkyl or haloalkyl, 3-10 membered cycloalkyl or heterocycloalkyl, or Rb and Rc, Rd and Re each form a C ═ O bond or a 3-6 membered carbocyclic or heterocyclic ring;
m and n are respectively and independently selected from integers of 0-3;
cy is selected from 3-10 membered cycloalkyl or heterocycloalkyl, 5-12 membered monocyclic or fused aromatic or heteroaromatic group;
r3 is selected from hydrogen, deuterium, halogen, C1-C10 alkyl or haloalkyl, 3-to 10-membered cycloalkyl or heterocycloalkyl, 5-to 12-membered aryl or heteroaryl, substituted or unsubstituted amino, hydroxyl, C1-C10 alkoxy or haloalkoxy, cyano, substituted or unsubstituted amide, substituted or unsubstituted sulfonamide, substituted or unsubstituted ureido, substituted or unsubstituted sulfonylureido, substituted or unsubstituted carbamoyl, substituted or unsubstituted phosphoryl, substituted or unsubstituted alkylphosphite, substituted or unsubstituted alkylsilyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acryloyl, substituted or unsubstituted propioloyl, haloacetyl or haloethylsulfonyl;
y is selected from N or CRy, Ry is independently selected from hydrogen, deuterium, halogen, hydroxy, amino, cyano, C1-C6 alkyl or haloalkyl, 3-10 membered cycloalkyl or heterocycloalkyl;
r4 is independently selected from the group consisting of hydrogen, deuterium, halogen, C1-C10 alkyl or haloalkyl, 3-to 10-membered cycloalkyl or heterocycloalkyl, 5-to 12-membered aryl or heteroaryl, substituted or unsubstituted amino, hydroxyl, C1-C10 alkoxy or haloalkoxy, cyano, substituted or unsubstituted amido, substituted or unsubstituted sulfonamide, substituted or unsubstituted ureido, substituted or unsubstituted sulfonylureido, substituted or unsubstituted carbamoyl, substituted or unsubstituted phosphoryl, substituted or unsubstituted alkylphosphite, substituted or unsubstituted alkylsilyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acryloyl, substituted or unsubstituted propioloyl, haloacetyl or haloethylsulfonyl
The above-mentioned substituted or unsubstituted substituents are each independently selected from the group consisting of: including but not limited to deuterium, halogen, hydroxy, monoalkylamino, dialkylamino, C1-C6 alkyl or haloalkyl, 3-10 membered cycloalkyl or heterocycloalkyl, cyano, C1-C6 alkoxy or haloalkoxy; wherein said heteroaryl group contains 1 to 3 heteroatoms selected from the group consisting of: n, O, P or S, the heterocycloalkyl group containing 1 to 3 heteroatoms selected from the group consisting of: n, O, P or S, said ring system including spiro, bridged, fused, etc. saturated or partially unsaturated ring systems.
In some of the preferred embodiments, the first and second,
R 1 independently selected from C1-C6 alkyl, C1-C6 haloalkyl, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, 5-8 membered heterocycloalkyl-O-, C1-C6 alkyl substituted amino, C1-C6 haloalkyl substituted amino, 3-8 membered cycloalkyl substituted amino, 3-8 membered heterocycloalkyl substituted amino; the R is 1 1 or more hydrogen atoms above may be optionally substituted with: halogen, hydroxyl, amino, cyano, mono C1-C3 alkylamino, di C1-C3 alkylamino, C1-C3 alkyl, hydroxyl-substituted C1-C3 alkyl, amino-substituted C1-C3 alkyl, C1-C3 alkoxy, 3-8 membered cycloalkyl C1-C3 alkyl-, 3-8 membered heterocycloalkyl-C1-C3 alkyl-, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl;
R 2 independently selected from C1-C6 alkyl, C1-C6 haloalkyl, 3-8 membered cycloalkyl or 3-8 membered heterocycloalkyl;
cy is selected from 5-8 membered cycloalkyl, 5-8 heterocycloalkyl, 6-10 membered monocyclic or fused aromatic group, 5-10 membered monocyclic or fused heteroaromatic group;
R 3 selected from hydrogen, deuterium, halogen, hydroxy, cyano, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkyl, C1-C6 haloalkyl, 3-6 membered cycloalkyl or heterocycloalkyl, 6-10 membered aryl, 5-8 membered heteroaryl, substituted or unsubstituted amino, substituted or unsubstituted amido;
R 4 independently selected from hydrogen, deuterium, halogen, hydroxy, cyano, C1-C6 alkyl, C1-C6 haloalkyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, 6-10 membered aryl, 5-8 membered heteroaryl, C1-C6 alkoxy, C1-C6 haloalkoxy, 3-6 membered cycloalkyl-C (O) -, 3-6 membered heterocycloalkyl-C (O) -, 3-6 membered cycloalkyl-O-C (O) -, 3-6 membered heterocycloalkyl-O-C (O) -, 6-10 membered aryl-C (O) -, 5-8 membered heteroaryl-C (O) -; the R is 4 Optionally substituted by R 41 Substituted, said R 41 Independently selected from: halogen, hydroxy, cyano, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, C1-C6 alkyl, C1-C6 haloalkyl, 3-6 membered cycloalkyl or heterocycloalkyl, C1-C6 alkoxy or haloalkoxy, C2-C6 alkenyl-C (O) -; the R is 41 May be further substituted with: halogen, hydroxy, cyano, mono-C1-C6 alkylamino, di-C1-C6 alkylamino.
In some preferred embodiments, R 1 Preferably, it is
Or, R 2 Preferably methyl, isopropyl;
In some preferred embodiments, the compound having the general formula (I), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsomer, solvate, polymorph or prodrug thereof, preferably is a compound represented by the general formula (II), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsomer, solvate, polymorph or prodrug thereof:
all radicals i.e. R 1 、R 2 、R 3 、R 4 、R a 、R b 、R c 、R d 、R e Cy, W, m, n ranges are as defined above.
In some preferred embodiments, it is preferably a compound of formula (III), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsiomer, solvate, polymorph or prodrug thereof:
all radicals i.e. R 1 、R 2 、R 3 、R 4 、R a 、R b 、R c 、R d 、R e Cy, W, m, n ranges are as defined above.
In some preferred embodiments, it is preferably a compound of formula (IV), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsiomer, solvate, polymorph or prodrug thereof:
wherein Cy1 is selected from 5-10 membered aryl or heteroaryl, Cy2 is selected from 3-12 membered saturated carbocyclic or heterocyclic groups, and the range of other groups is as defined above.
In some embodiments, it is preferably a compound of formula (V), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsiomer, solvate, polymorph or prodrug thereof:
r1 is preferably selected from C1-C6 alkyl, such as methyl; substituted or unsubstituted 5-6 membered saturated ring such as cyclohexyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl and the like; substituted or unsubstituted 5-6 membered saturated cyclic group ethers such as cyclohexyl ether, piperidinyl ether, tetrahydropyranyl ether; substituted or unsubstituted 5-6 membered saturated cyclic amines, such as cyclohexylamino, piperidinamino, tetrahydropyrylamino; substituted or unsubstituted 5-6 membered saturated cyclic alkylene ethers such as piperidylmethylene ether; substituted or unsubstituted 5-6 membered saturated cyclylalkyleneamine, such as piperidinylidenemethylamine; the substituent is preferably selected from deuterium, halogen, amino, hydroxyl, dimethylamino, methoxy, hydroxymethyl, aminomethyl and the like; the ranges for the other groups are as defined above.
A method for preparing the compound of the formula I is characterized in that the compound of the general formula (A) and an amino compound (B) are subjected to nucleophilic substitution reaction under the catalysis of alkali or acid to generate the compound of the general formula (I);
the definition of each group is as described above;
preferably, the reaction is carried out in a solvent, and the solvent is selected from the group consisting of: water, methanol, ethanol, isopropanol, butanol, ethylene glycol methyl ether, N-methyl pyrrolidone, dimethyl sulfoxide, tetrahydrofuran, toluene, dichloromethane, 1, 2-dichloroethane, acetonitrile, N-dimethylformamide, N-dimethylacetamide, dioxane, or a combination thereof.
Preferably, the inorganic base is selected from the group consisting of: sodium hydride, potassium hydroxide, sodium acetate, potassium tert-butoxide, sodium tert-butoxide, potassium fluoride, cesium fluoride, potassium phosphate, potassium carbonate, potassium bicarbonate, sodium carbonate, sodium bicarbonate, or combinations thereof; the organic base is selected from the group consisting of: pyridine, triethylamine, N, N-diisopropylethylamine, 1, 8-diazabicyclo [5.4.0] undec-7-ene (DBU), lithium hexamethyldisilazide, sodium hexamethyldisilazide, lutidine, or a combination thereof.
Preferably, the acid is selected from the group consisting of: hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, toluenesulfonic acid, trifluoroacetic acid, formic acid, acetic acid, trifluoromethanesulfonic acid, or combinations thereof.
The invention provides a class of preferred compounds of formula (I) including, but not limited to, the following structures:
structural formula of example
Another objective of the invention is to provide a medicament for treating or preventing tumor or autoimmune diseases and a composition thereof. The technical scheme for realizing the purpose is as follows:
in one aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I, a stereoisomer, geometric isomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof, and a pharmaceutically acceptable carrier. In certain embodiments of the pharmaceutical composition, the pharmaceutical composition is formulated for intravenous administration, intramuscular administration, oral administration, rectal administration, inhalation administration, nasal administration, topical administration, ocular administration, or otic administration. In other embodiments of the pharmaceutical composition, the pharmaceutical composition is a tablet, pill, capsule, liquid, inhalant, nasal spray solution, suppository, solution, emulsion, ointment, eye drop, or ear drop. In other embodiments of the pharmaceutical composition, it further comprises one or more additional therapeutic agents.
In another aspect, the present invention provides the use of a compound of formula I, a stereoisomer, geometric isomer, tautomer, pharmaceutically acceptable salt, or prodrug thereof in the manufacture of a medicament for the prevention, treatment, or alleviation of a disorder or disease mediated by abnormal activity of a CDK kinase, particularly CDK7 kinase.
In another aspect, the present invention provides an amino-substituted aromatic heterocyclic pyrazole compound represented by the general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, tautomer, solvate, polymorph or prodrug thereof, for use in the preparation of a method for treating or preventing a proliferative disease (e.g., cancer (e.g., leukemia, melanoma, multiple myeloma), benign neoplasm, angiogenesis, inflammatory disease, autoinflammatory disease and autoimmune disease) in a subject, wherein the tumor is independently selected from the group consisting of non-small cell lung cancer, lung adenocarcinoma, squamous cell carcinoma, breast cancer, prostate cancer, liver cancer, skin cancer, stomach cancer, intestinal cancer, cholangiocarcinoma, brain cancer, leukemia, lymph cancer, fibroma sarcoma, basal cell carcinoma, colon cancer, and prostate cancer, Glioma, renal cancer, melanoma, osteocarcinoma, thyroid cancer, nasopharyngeal carcinoma, pancreatic cancer, etc.; the autoimmune disease is independently selected from rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, hemolytic anemia, or psoriasis; the inflammatory disease is independently selected from osteoarthritis, gouty arthritis, ulcerative colitis, inflammatory bowel disease and/or the like; the infectious disease is independently selected from sepsis, septic shock, endotoxic shock, gram-negative sepsis, and/or toxic shock syndrome.
The invention relates to a novel compound with the structural characteristics of a general formula (I), which selectively inhibits the enzyme activity of CDK7, obviously inhibits the growth of various tumor cells, and is a treatment drug with a brand-new action mechanism.
It is to be understood that within the scope of the present invention, the above-described features of the present invention and those specifically described below (e.g., in the examples) may be combined with each other to form new or preferred embodiments. The space is not described herein in a repeated fashion.
Detailed Description
The inventors have long and intensively studied to prepare a class of amino-substituted heteroaromatic pyrazole compounds having a novel structure shown in formula I, and found that the compounds have a good activity of inhibiting cyclin-dependent kinase 7(CDK7), and the compounds have a specific inhibitory effect on cyclin-dependent kinase 7(CDK7) at a very low concentration (which can be as low as less than 10nM), and are excellent in a cell proliferation inhibitory activity related to CDK7, and thus can be used for treating diseases such as tumors related to the abnormal activity of cyclin-dependent kinase 7(CDK 7). Based on the above findings, the inventors have completed the present invention.
Term(s) for
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. All patents, patent applications, and publications cited herein are incorporated by reference in their entirety unless otherwise indicated.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the subject matter claimed. In this application, the use of the singular also includes the plural unless specifically stated otherwise. It must be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. It should also be noted that the use of "or", "or" means "and/or" unless stated otherwise. Furthermore, the term "comprising" as well as other forms, such as "includes," "including," and "containing," are not limiting.
Definitions for the terms of the standardization sector can be found in the literature references including Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4TH ED." Vols.A (2000) and B (2001), Plenum Press, New York. Unless otherwise indicated, conventional methods within the skill of the art are employed, such as mass spectrometry, NMR, IR and UV/VIS spectroscopy, and pharmacological methods. Unless a specific definition is set forth, the terms used herein in the pertinent description of analytical chemistry, organic synthetic chemistry, and pharmaceutical chemistry are known in the art. Standard techniques can be used in chemical synthesis, chemical analysis, pharmaceutical preparation, formulation and delivery, and treatment of patients. For example, the reaction and purification can be carried out using the instructions of the kit from the manufacturer, or according to the methods known in the art or the instructions of the present invention. The techniques and methods described above can generally be practiced according to conventional methods well known in the art, as described in various general and more specific documents referred to and discussed in this specification. In the present specification, groups and substituents thereof may be selected by one skilled in the art to provide stable moieties and compounds.
When a substituent is described by a general formula written from left to right, the substituent also includes chemically equivalent substituents obtained when the formula is written from right to left. For example, -CH 2O-is equivalent to-OCH 2-.
The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, operating manuals, and treatises, are hereby incorporated by reference in their entirety.
Certain chemical groups defined herein are preceded by a shorthand notation to indicate the total number of carbon atoms present in the group. For example, C1-6 alkyl refers to an alkyl group as defined below having a total of 1 to 6 carbon atoms. The total number of carbon atoms in the shorthand notation excludes carbons that may be present in a substituent of the group.
In addition to the foregoing, the following terms, when used in the specification and claims of this application, have the meanings indicated below, unless otherwise specifically indicated.
In the present application, the term "halogen" means fluorine, chlorine, bromine or iodine; "hydroxy" means an-OH group; "hydroxyalkyl" refers to an alkyl group as defined below substituted with a hydroxyl (-OH) group; "carbonyl" refers to a-C (═ O) -group; "Nitro" means-NO 2 (ii) a "cyano" means-CN; "amino" means-NH 2 (ii) a "substituted amino" refers to an amino group substituted with one or two alkyl, alkylcarbonyl, aralkyl, heteroaralkyl groups as defined below, e.g., monoalkylamino, dialkylamino, alkylamido, aralkylamino, heteroaralkylamino; "carboxyl" means-COOH.
In the present application, the term "alkyl", as a group or as part of another group (e.g. as used in groups such as halogen-substituted alkyl), means a straight or branched hydrocarbon chain group consisting only of carbon and hydrogen atoms, containing no unsaturated bonds, having, for example, from 1 to 12 (preferably from 1 to 8, more preferably from 1 to 6) carbon atoms and being attached to the rest of the molecule by single bonds. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, 2-dimethylpropyl, n-hexyl, heptyl, 2-methylhexyl, 3-methylhexyl, octyl, nonyl, decyl, and the like.
In the present application, the term "alkenyl" as a group or part of another group means a straight or branched hydrocarbon chain group consisting of only carbon atoms and hydrogen atoms, containing at least one double bond, having, for example, 2 to 14 (preferably 2 to 10, more preferably 2 to 6) carbon atoms, and attached to the rest of the molecule by a single bond, such as, but not limited to, vinyl, propenyl, allyl, but-1-enyl, but-2-enyl, pent-1, 4-dienyl, and the like.
In the present application, the term "alkynyl" as a group or part of another group means a straight or branched hydrocarbon chain group consisting solely of carbon and hydrogen atoms, containing at least one triple bond and optionally one or more double bonds, having for example 2 to 14 (preferably 2 to 10, more preferably 2 to 6) carbon atoms and being connected to the rest of the molecule by single bonds, such as but not limited to ethynyl, prop-1-ynyl, but-1-ynyl, pent-1-en-4-ynyl and the like.
In the present application, the term "cycloalkyl" as a group or part of another group means a stable non-aromatic monocyclic or polycyclic hydrocarbon group consisting of only carbon atoms and hydrogen atoms, which may include fused, bridged or spiro ring systems, having 3 to 15 carbon atoms, preferably having 3 to 10 carbon atoms, more preferably having 3 to 8 carbon atoms, and which is saturated or unsaturated and may be attached to the rest of the molecule by a single bond via any suitable carbon atom. Unless otherwise specifically indicated in the specification, carbon atoms in cycloalkyl groups may be optionally oxidized. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cyclooctyl, 1H-indenyl, 2, 3-indanyl, 1,2,3, 4-tetrahydro-naphthyl, 5,6,7, 8-tetrahydro-naphthyl, 8, 9-dihydro-7H-benzocyclohepten-6-yl, 6,7,8, 9-tetrahydro-5H-benzocycloheptenyl, 5,6,7,8,9, 10-hexahydro-benzocyclooctenyl, fluorenyl, bicyclo [2.2.1] heptyl, 7-dimethyl-bicyclo [2.2.1] heptyl, bicyclo [2.2.1] heptenyl, bicyclo [2.2.2] octyl, bicyclo [3.1.1] heptyl, bicyclo [3.2.1] octyl, bicyclo [2.2.2] octenyl, Bicyclo [3.2.1] octenyl, adamantyl, octahydro-4, 7-methylene-1H-indenyl, octahydro-2, 5-methylene-pentalenyl and the like.
In this application, the term "heterocyclyl" as a group or part of another group means a stable 3-to 20-membered non-aromatic cyclic group consisting of 2 to 14 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, phosphorus, oxygen, and sulfur. Unless otherwise specifically indicated in the specification, a heterocyclic group may be a monocyclic, bicyclic, tricyclic or higher ring system, which may include fused ring systems, bridged ring systems or spiro ring systems; wherein the nitrogen, carbon or sulfur atom in the heterocyclic group thereof may be optionally oxidized; the nitrogen atoms may optionally be quaternized; and the heterocyclic group may be partially or fully saturated. The heterocyclic group may be attached to the rest of the molecule via a carbon atom or a heteroatom and by a single bond. In heterocyclic groups containing fused rings, one or more of the rings may be aryl or heteroaryl as defined below, provided that the point of attachment to the rest of the molecule is a non-aromatic ring atom. For the purposes of the present invention, heterocyclyl is preferably a stable 4-to 11-membered non-aromatic monocyclic, bicyclic, bridged or spiro group containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, more preferably a stable 4-to 8-membered non-aromatic monocyclic, bicyclic, bridged or spiro group containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur. Examples of heterocyclyl groups include, but are not limited to: pyrrolidinyl, morpholinyl, piperazinyl, homopiperazinyl, piperidinyl, thiomorpholinyl, 2, 7-diaza-spiro [3.5] nonan-7-yl, 2-oxa-6-aza-spiro [3.3] heptan-6-yl, 2, 5-diaza-bicyclo [2.2.1] heptan-2-yl, azetidinyl, pyranyl, tetrahydropyranyl, thiopyranyl, tetrahydrofuranyl, oxazinyl, dioxolanyl, tetrahydroisoquinolinyl, decahydroisoquinolinyl, imidazolinyl, imidazolidinyl, quinolizinyl, thiazolidinyl, isothiazolidinyl, isoxazolidinyl, dihydroindolyl, octahydroindolyl, octahydroisoindolyl, pyrrolidinyl, pyrazolidinyl, phthalimido, and the like.
In this application, the term "aryl" as a group or as part of another group means a conjugated hydrocarbon ring system group having 6 to 18 carbon atoms, preferably having 6 to 10 carbon atoms. For the purposes of the present invention, an aryl group may be a monocyclic, bicyclic, tricyclic or higher polycyclic ring system and may also be fused to a cycloalkyl or heterocyclic group as defined above, provided that the aryl group is attached to the remainder of the molecule by a single bond via an atom on the aromatic ring. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, anthracenyl, phenanthrenyl, fluorenyl, 2, 3-dihydro-1H-isoindolyl, 2-benzoxazolinone, 2H-1, 4-benzoxazin-3 (4H) -one-7-yl, and the like.
In the present application, the term "arylalkyl" refers to an alkyl group as defined above substituted with an aryl group as defined above.
In this application, the term "heteroaryl" as a group or part of another group means a 5-to 16-membered conjugated ring system group having 1 to 15 carbon atoms (preferably having 1 to 10 carbon atoms) and 1 to 6 heteroatoms selected from nitrogen, oxygen and sulfur in the ring. Unless otherwise specifically indicated in the specification, a heteroaryl group may be a monocyclic, bicyclic, tricyclic or higher ring system, and may also be fused to a cycloalkyl or heterocyclic group as defined above, provided that the heteroaryl group is attached to the rest of the molecule by a single bond via an atom on the aromatic ring. The nitrogen, carbon or sulfur atoms in the heteroaryl group may be optionally oxidized; the nitrogen atoms may optionally be quaternized. For the purposes of the present invention, heteroaryl is preferably a stable 5-to 12-membered aromatic group containing 1 to 5 heteroatoms selected from nitrogen, oxygen and sulfur, more preferably a stable 5-to 10-membered aromatic group containing 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur or a 5-to 6-membered aromatic group containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur. Examples of heteroaryl groups include, but are not limited to, thienyl, imidazolyl, pyrazolyl, thiazolyl, oxazolyl, oxadiazolyl, isoxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzimidazolyl, benzopyrazolyl, indolyl, furyl, pyrrolyl, triazolyl, tetrazolyl, triazinyl, indolizinyl, isoindolyl, indazolyl, isoindolyl, purinyl, quinolyl, isoquinolyl, diazonaphthyl, naphthyridinyl, quinoxalinyl, pteridinyl, carbazolyl, carbolinyl, phenanthridinyl, phenanthrolinyl, acridinyl, phenazinyl, isothiazolyl, benzothiazolyl, benzothienyl, oxazolyl, cinnolinyl, quinazolinyl, thiophenyl, indolizinyl, orthophenanthrolidinyl, isoxazolyl, phenoxazinyl, phenothiazinyl, 4,5,6, 7-tetrahydrobenzo [ b ] thienyl, naphthopyridyl, pyridinyl, and the like, [1,2,4] triazolo [4,3-b ] pyridazine, [1,2,4] triazolo [4,3-a ] pyrazine, [1,2,4] triazolo [4,3-c ] pyrimidine, [1,2,4] triazolo [4,3-a ] pyridine, imidazo [1,2-b ] pyridazine, imidazo [1,2-a ] pyrazine and the like.
In the present application, the term "heteroarylalkyl" refers to an alkyl group as defined above substituted with a heteroaryl group as defined above.
In this application, "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event or circumstance occurs and instances where it does not. For example, "optionally substituted aryl" means that the aryl group is substituted or unsubstituted, and the description includes both substituted and unsubstituted aryl groups.
The terms "moiety," "structural moiety," "chemical moiety," "group," "chemical group" as used herein refer to a specific fragment or functional group in a molecule. Chemical moieties are generally considered to be chemical entities that are embedded in or attached to a molecule.
"stereoisomers" refers to compounds that consist of the same atoms, are bonded by the same bonds, but have different three-dimensional structures. The present invention is intended to cover various stereoisomers and mixtures thereof.
When the compounds of the present invention contain olefinic double bonds, the compounds of the present invention are intended to include both E-and Z-geometric isomers unless otherwise specified.
"tautomer" refers to an isomer formed by the transfer of a proton from one atom of a molecule to another atom of the same molecule. All tautomeric forms of the compounds of the invention are also intended to be included within the scope of the invention.
The compounds of the present invention or pharmaceutically acceptable salts thereof may contain one or more chiral carbon atoms and may therefore give rise to enantiomers, diastereomers and other stereoisomeric forms. Each chiral carbon atom may be defined as (R) -or (S) -, based on stereochemistry. The present invention is intended to include all possible isomers, as well as racemates and optically pure forms thereof. The compounds of the invention may be prepared by selecting as starting materials or intermediates racemates, diastereomers or enantiomers. Optically active isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, e.g., crystallization and chiral chromatography.
Conventional techniques for the preparation/separation of individual isomers include Chiral synthesis from suitable optically pure precursors, or resolution of racemates (or racemates of salts or derivatives) using, for example, Chiral high performance liquid chromatography, as described, for example, in Gerald Gubitz and Martin G.Schmid (Eds.), Chiral Separations, Methods and Protocols, Methods in Molecular Biology, Vol.243, 2004; m. Stalcup, Chiral Separations, Annu. Rev. anal. chem.3:341-63, 2010; fumiss et al (eds.), VOGEL' S ENCYCOPEDIA OF PRACTICAL ORGANIC CHEMISTRY 5. TH ED., Longman Scientific and Technical Ltd., Essex,1991, 809-816; heller, acc, chem, res, 1990,23,128.
In the present application, the term "pharmaceutically acceptable salts" includes pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
"pharmaceutically acceptable acid addition salts" refers to salts with inorganic or organic acids which retain the biological effectiveness of the free base without other side effects. Inorganic acid salts include, but are not limited to, hydrochloride, hydrobromide, sulfate, nitrate, phosphate, and the like; organic acid salts include, but are not limited to, formates, acetates, 2-dichloroacetates, trifluoroacetates, propionates, caproates, caprylates, caprates, undecylenates, glycolates, gluconates, lactates, sebacates, adipates, glutarates, malonates, oxalates, maleates, succinates, fumarates, tartrates, citrates, palmitates, stearates, oleates, cinnamates, laurates, malates, glutamates, pyroglutamates, aspartates, benzoates, methanesulfonates, benzenesulfonates, p-toluenesulfonates, alginates, ascorbates, salicylates, 4-aminosalicylates, napadisylates, and the like. These salts can be prepared by methods known in the art.
"pharmaceutically acceptable base addition salts" refers to salts with inorganic or organic bases which maintain the biological effectiveness of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like. Preferred inorganic salts are ammonium, sodium, potassium, calcium and magnesium salts. Salts derived from organic bases include, but are not limited to, the following: primary, secondary and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like. Preferred organic bases include isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline, and caffeine. These salts can be prepared by methods known in the art.
"polymorph" refers to different solid crystalline phases of certain compounds of the present invention in the solid state due to the presence of two or more different molecular arrangements. Certain compounds of the present invention may exist in more than one crystalline form and the present invention is intended to include the various crystalline forms and mixtures thereof.
Typically, crystallization will result in solvates of the compounds of the invention. The term "solvate" as used herein refers to an aggregate comprising one or more molecules of the compound of the present invention and one or more solvent molecules. The solvent may be water, in which case the solvate is a hydrate. Alternatively, the solvent may be an organic solvent. Thus, the compounds of the present invention may exist as hydrates, including monohydrates, dihydrate, hemihydrate, sesquihydrates, trihydrate, tetrahydrate, and the like, as well as the corresponding solvated forms. The compounds of the invention may form true solvates, but in some cases it is also possible to retain only adventitious water or a mixture of water plus a portion of adventitious solvent. The compounds of the invention may be reacted in a solvent or precipitated or crystallized from a solvent. Solvates of the compounds of the invention are also included within the scope of the invention.
The invention also includes prodrugs of the above compounds. In the present application, the term "prodrug" denotes a compound that can be converted under physiological conditions or by solvolysis to the biologically active compound of the invention. Thus, the term "prodrug" refers to a pharmaceutically acceptable metabolic precursor of a compound of the invention. Prodrugs may not be active when administered to a subject in need thereof, but are converted in vivo to the active compounds of the invention. Prodrugs are generally rapidly converted in vivo to yield the parent compound of the invention, for example, by hydrolysis in blood. Prodrug compounds generally provide the advantages of solubility, histocompatibility, or sustained release in mammalian organisms. Prodrugs include known amino protecting groups and carboxyl protecting groups. Specific methods for preparing prodrugs can be found in Saulnier, M.G., et al, bioorg.Med.chem.Lett.1994,4, 1985-1990; greenwald, r.b., et al, j.med.chem.2000,43,475.
In the present application, a "pharmaceutical composition" refers to a formulation of a compound of the present invention with a vehicle generally accepted in the art for delivery of biologically active compounds to a mammal (e.g., a human). The medium includes a pharmaceutically acceptable carrier. The purpose of the pharmaceutical composition is to facilitate administration to an organism, facilitate absorption of active ingredients and exert biological activity.
The term "pharmaceutically acceptable" as used herein refers to a substance (e.g., carrier or diluent) that does not affect the biological activity or properties of the compounds of the present invention and is relatively non-toxic, i.e., the substance can be administered to an individual without causing an adverse biological response or interacting in an adverse manner with any of the components contained in the composition.
As used herein, a "pharmaceutically acceptable carrier" includes, but is not limited to, any adjuvant, carrier, excipient, glidant, sweetener, diluent, preservative, dye/colorant, flavoring agent, surfactant, wetting agent, dispersing agent, suspending agent, stabilizing agent, isotonic agent, solvent, or emulsifying agent that is approved by the relevant governmental regulatory agency for human or livestock use.
The "tumor" and "diseases related to abnormal cell proliferation" include, but are not limited to, leukemia, gastrointestinal stromal tumor, histiocytic lymphoma, non-small cell lung cancer, pancreatic cancer, squamous cell lung cancer, lung adenocarcinoma, breast cancer, prostate cancer, liver cancer, skin cancer, epithelial cell cancer, cervical cancer, ovarian cancer, intestinal cancer, nasopharyngeal cancer, brain cancer, bone cancer, esophageal cancer, melanoma, renal cancer, oral cancer, and the like.
The terms "preventing," "prevention," and "prevention" as used herein include reducing the likelihood of occurrence or worsening of a disease or disorder in a patient.
As used herein, the term "treatment" and other similar synonyms include the following meanings:
(i) preventing the occurrence of a disease or condition in a mammal, particularly when such mammal is susceptible to the disease or condition, but has not been diagnosed as having the disease or condition;
(ii) inhibiting the disease or disorder, i.e., arresting its development;
(iii) alleviating the disease or condition, i.e., causing regression of the state of the disease or condition; or
(iv) Alleviating the symptoms caused by the disease or disorder.
The terms "effective amount," "therapeutically effective amount," or "pharmaceutically effective amount" as used herein, refer to an amount of at least one agent or compound that is sufficient to alleviate one or more symptoms of the disease or disorder being treated to some extent after administration. The result may be a reduction and/or alleviation of signs, symptoms, or causes, or any other desired change in a biological system. For example, an "effective amount" for treatment is the amount of a composition comprising a compound disclosed herein that is clinically necessary to provide a significant remission effect of the condition. An effective amount suitable in any individual case can be determined using techniques such as a dose escalation assay.
The terms "administering," "administration," "administering," and the like as used herein refer to a method capable of delivering a compound or composition to a desired site for biological action. These methods include, but are not limited to, oral routes, via the duodenal route, parenteral injection (including intravenous, subcutaneous, intraperitoneal, intramuscular, intraarterial injection or infusion), topical administration, and rectal administration. Administration techniques useful for The compounds and methods described herein are well known to those skilled in The art, for example, in Goodman and Gilman, The pharmaceutical Basis of Therapeutics, current ed.; pergamon; and Remington's, Pharmaceutical Sciences (current edition), Mack Publishing Co., Easton, Pa. In preferred embodiments, the compounds and compositions discussed herein are administered orally.
The terms "drug combination", "administering other treatment", "administering other therapeutic agent" and the like as used herein refer to a drug treatment obtained by mixing or combining more than one active ingredient, including fixed and unfixed combinations of active ingredients. The term "fixed combination" refers to the simultaneous administration of at least one compound described herein and at least one co-agent to a patient in the form of a single entity or a single dosage form. The term "non-fixed combination" refers to the simultaneous administration, concomitant administration, or sequential administration at variable intervals of at least one compound described herein and at least one synergistic formulation to a patient as separate entities. These also apply to cocktail therapy, for example the administration of three or more active ingredients.
It will also be appreciated by those skilled in the art that in the processes described below, the functional groups of the intermediate compounds may need to be protected by suitable protecting groups. Such functional groups include hydroxyl, amino, mercapto and carboxylic acid. Suitable hydroxy protecting groups include trialkylsilyl or diarylalkylsilyl groups (e.g.tert-butyldimethylsilyl, tert-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino include t-butyloxycarbonyl, benzyloxycarbonyl and the like. Suitable thiol protecting groups include-C (O) -R "(where R" is alkyl, aryl or aralkyl), p-methoxybenzyl, trityl and the like. Suitable carboxyl protecting groups include alkyl, aryl or aralkyl esters.
Protecting groups may be introduced and removed according to standard techniques known to those skilled in the art and as described herein. The use of protecting Groups is described in detail in Greene, T.W. and P.G.M.Wuts, Protective Groups in Organic Synthesis, (1999),4th Ed., Wiley. The protecting group may also be a polymeric resin.
The invention will be further illustrated with reference to specific examples. It should be understood that these examples are for illustrative purposes only and are not intended to limit the scope of the present invention. Experimental procedures without specific conditions noted in the following examples, generally according to conventional conditions, or according to conditions recommended by the manufacturer. Percentages and parts are by weight unless otherwise indicated.
In each example, the laboratory instruments are described (e.g. 1 H NMR was recorded by a nuclear magnetic resonance apparatus of the Varian Mercury-300 or Varian Mercury-400 type, 13 c NMR is recorded by a nuclear magnetic resonance apparatus of the Varian Mercury-400 or Varian Mercury-500 or Varian Mercury-600 type, chemical shifts are expressed in delta (ppm); mass spectra were recorded on a Finnigan/MAT-95(EI) and Finnigan LCQ/DECA and Micromass Ultra Q-TOF (ESI) type mass spectrometer; silica gel for reverse phase preparative HPLC separation 200-300 mesh).
Wherein, the chemical formula or the Chinese name table of the reagent represented by the English letter abbreviation is as follows:
iPrOH: isopropyl alcohol; EtOH: ethanol; DCM: dichloromethane; TFA: trifluoroacetic acid; MeOH: methanol; NaOH: sodium hydroxide; HCl: hydrogen chloride; TEA: triethylamine; raney Ni: raney nickel; 1, 4-dioxane: 1, 4-dioxane; NaH: sodium hydride; h 2 O: water; Pd/C: palladium on carbon; h 2 : hydrogen gas; HATU: 2- (7-benzotriazole oxide) -N, N, N ', N' -tetramethyluronium hexafluorophosphate; DMF: n, N-dimethylformamide; THF: tetrahydrofuran; boc 2 O: di-tert-butyl dicarbonate; NBS: n-bromosuccinimide; NCS: n-chlorosuccinimide; NIS: n-iodosuccinimide; MeCN: acetonitrile; DIPEA/DIEA: n, N-diisopropylethylamine; NaBH 4 : sodium borohydride; AcOH: acetic acid; ethyl acetate: ethyl acetate; NaBH 3 CN: sodium cyanoborohydride; k 2 CO 3 : potassium carbonate; cs 2 CO 3 : cesium carbonate; nBuLi:n-butyl lithium; LiAlH 4 : lithium aluminum hydride; pd (dppf) Cl 2 : [1, 1' -bis (diphenylphosphino) ferrocene]Palladium dichloride; KOAc (Koac): and (4) potassium acetate. Fumaronitril: nitrile fumarate; p (nBu) 3 : tri-n-butylphosphine; LDA: lithium diisopropylamide; LiOH: lithium hydroxide; MeI: methyl iodide; EtI: ethyl iodide; (CH) 2 O) n : paraformaldehyde; HCO 2 H: formic acid; CH (CH) 3 COCl: acetyl chloride; LCMS: liquid chromatography-mass spectrometry; xantphos: 4, 5-bis diphenylphosphino-9, 9-dimethylxanthene; TLC: thin layer chromatography; eq.: equivalent weight; DCE: 1, 2-dichloroethane; HEPES (high efficiency particulate air): 4-hydroxyethylpiperazine ethanesulfonic acid; EGTA: ethylene glycol bis (2-aminoethyl ether) tetraacetic acid; DTT: dithiothreitol
Examples general preparation method
The pyrazolocyclochloride intermediate (1eq.) is dissolved in acetonitrile, DIPEA (1.6eq.) and benzylamine intermediate (1.0eq.) are added in sequence, and the mixture is heated to 70 ℃ under the protection of nitrogen and stirred for 12 hours. TLC monitoring reaction is completed, cooling to room temperature, decompression concentration, silica gel column chromatography separation and purification of the remainder to obtain target product, and nuclear magnetic and mass spectrum are adopted to confirm the structure.
Or dissolving the product (1eq.) in methanol, adding hydrochloric acid aqueous solution/hydrochloric acid alcoholic solution (20eq.) or hydrobromic acid/acetic acid (10eq.), stirring at room temperature or heating for 3-10 hours to remove Boc and/or Cbz protecting groups, performing column chromatography separation and purification after conventional treatment to obtain a target product, and confirming the structure by nuclear magnetism and mass spectrometry;
or dissolving the product (1eq.) in methanol, and removing the protecting groups such as Cbz/benzyl under the catalysis of palladium carbon in hydrogen atmosphere. TLC monitoring reaction is complete, decompression concentration is carried out, the remainder is separated and purified by silica gel column chromatography to obtain a target product, and nuclear magnetism and mass spectrum are adopted to confirm the structure;
or dissolving the product (1eq.) in a proper solvent, performing proper conversion through conventional functional group conversion, such as carbonyl reagent acylation, acid-amine condensation, reductive amination, halide alkylation, metal reagent cross-coupling and other reactions to obtain a target product, and confirming the structure by nuclear magnetism and mass spectrometry.
Preparation of key intermediate:
examples preparation
Example 1: n- (2- (4-aminopiperidin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) -1,2,3, 4-tetrahydroisoquinolin-4-amine
The first step is as follows: intermediate A (30mg,0.1mmol), tert-butyl 4-amino-3, 4-dihydroisoquinoline-2 (1H) carbonate (49mg,0.2mmol), DIEA (78mg,0.6mmol) were dissolved in acetonitrile (5mL) under nitrogen and reacted at 70 ℃ for 4H. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (PE: EA ═ 2:1) to give intermediate product B (70mg) as a yellow oil. LC-MS [ M + H ]] + :m/z 641.3。
The second step is that: the above intermediate product B (70mg) was dissolved in 6N HCl aqueous solution (5mL), heated to 70 ℃ and reacted with stirring for 4 hours. The reaction solution was cooled to room temperature, neutralized to pH 8-9 by adding aqueous ammonia, and extracted three times with dichloromethane (50 mL). The separated organic phase was over MgSO 4 Drying, filtering and concentrating. The crude product was purified by HPLC prep. to give the desired product as a yellow solid (37 mg). LC-MS [ M + H ]] + :m/z 407.2。 1 H-NMR(400MHz,MeOD-d 4 ):δ7.73(s,1H),7.49-7.32(m,4H),5.83(t,J=6.0Hz,1H),4.91-4.83(m,2H),4.53-4.43(m,2H),3.81-3.71(m,2H),3.41-3.37(m,1H),3.08-2.99(m,3H),2.07-2.04(m,2H),1.61-1.52(m,2H),1.29(d,J=6.8Hz,6H)。
Chiral preparative separation of the A1 intermediate gave intermediates A1-1 and A1-2, respectively, which were deprotected in accordance with the procedure described above for the second reaction to give examples 1-1 and 1-2. The preparation conditions are as follows: separation column (SunFire Prep C18 OBDTM,10um, 19 x 250 mm); gradient (5% -95% acetonitrile/0.1% formic acid/water, 16min, flow 20 mL/min). Analysis conditions were as follows: analytical column (Waters SunFire C18, 4.6 x 50mm, 5 um); gradient (5% -95% acetonitrile/0.1% formic acid/water, 3.0min, flow rate 2.0mL/min, 2.6 min); column temperature: 40 ℃; detection wavelength: 254 nM.
Starting from intermediate a, and various aromatic and saturated ring-substituted amines, the syntheses described in example 1 gave examples 2-36;
example 17: 1- (8-isopropyl-4- ((-1,2,3, 4-tetrahydroisoquinolin-4-yl) amine) pyrazolo [1,5, -a ] [1,3,5] triazin-2-yl) piperidin-4-ol
The first step is as follows: intermediate B (73mg,0.3mmol), tert-butyl 4-amino-3, 4-dihydroisoquinoline-2 (1H) carbonate (74mg,0.32mmol), DIEA (78mg,0.6mmol) was dissolved in acetonitrile (10mL) under nitrogen and reacted at 70 ℃ for 4H. Concentrating the reaction solution under reduced pressure, and purifying the crude product by silica gel column chromatography (PE: EA ═ 2:1) to obtain a yellow oily intermediateProduct (80 mg). LC-MS [ M + H ]] + :m/z 455.6。
The second step is that: to a solution of the above intermediate compound (80mg,0.17mmol) in dichloromethane (10mL) was added m-chloroperoxybenzoic acid (75mg, 0.34mmol, 80% purity) with ice bath cooling. After the reaction temperature was slowly raised to room temperature, the reaction was stirred for further 3 hours. After the LC-MS detection reaction is completed, adding saturated NaSO into the reaction solution 3 Aqueous solution (10mL) and dichloromethane (20mL) and the organic phase was separated. The aqueous phase was washed twice more with dichloromethane (20 mL). The organic phases are combined and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (PE: EA ═ 2:1) to give the product as a yellow solid (50 mg). LC-MS [ M + H ]] + :m/z 487.6。
The third step: the above intermediate compound (50.0mg, 0.10mmol) and tetrahydroxypiperidine (61mg, 0.6mmol) were dissolved in NMP (1mL), DIEA (68mg, 0.62mmol) was added, and the mixture was heated to 115 ℃ and reacted overnight. After completion of the TLC detection, water (40mL) and ethyl acetate (40mL) were added. The separated aqueous phase was extracted twice with ethyl acetate (40 mL). The combined organic phases were concentrated under reduced pressure and dried to give an intermediate (30mg) as a white solid. LC-MS [ M + H ]] + :m/z 508.6.
The fourth step: trifluoroacetic acid (3mL) was added to the above intermediate compound (30mg,0.06mmol) in dichloromethane (10mL), and the reaction was stirred at room temperature for 4 hours. Ammonia was added to neutralize to pH 8-9 and extracted three times with dichloromethane (30 mL). The combined organic phases were concentrated under reduced pressure. The crude product was purified by HPLC prep. to give the desired product as a white solid (21 mg). LC-MS [ M + H ]] + :m/z 408.1。 1 H NMR(400MHz,MeOD-d 4 ):δ7.75(s,1H),7.50-7.52(m,1H),7.40-7.42(m,2H),7.32-7.34(m,1H),5.81(m,1H),4.47-4.52(m,2H),4.37-4.39(m,2H),3.87-3.91(m,1H),3.75-3.79(m,2H),3.47-3.40(m,2H),3.05-3.09(m,1H),1.89-1.93(m,2H),1.51(m,2H),1.24-1.31(d,J=7.2Hz,6H).
Intermediate B and different aromatic and saturated ring-substituted amines and heterocycloalkyl alcohols or heterocycloalkylamines as starting materials are synthesized according to the method of example 17 to give examples 18-26;
example 27: n- (5- (4- (dimethylamino) piperidin-1-yl) -3-isopropylpyrazolo [1, 5-a ] pyridin-7-yl) -1,2,3, 4-tetrahydroisoquinolin-4-amine
The first step is as follows: intermediate C (60.0mg, 0.26mmol) was dissolved in ethanol (5mL), DIEA (1mL) and tert-butyl 4-amino-3, 4-dihydroisoquinoline-2 (1H) carbonate (74mg,0.32mmol) were added, and the mixture was stirred under reflux for 8 hours. After completion of the reaction was detected by LC-MS, water (50mL) and ethyl acetate (50mL) were added to the reaction mixture, followed by extraction twice with ethyl acetate (50mL), and the separated organic phase was concentrated under reduced pressure and dried to give a yellow solid intermediate product (92 mg). LC-MS [ M + H ]] + :m/z 443.1。
The second step is that: to a solution of the above intermediate (92mg,0.21mmol) in toluene (10mL) was added 4-N, N-dimethylaminopiperidine (54mg,0.42mmol), Pd 2 (dba) 3 (3mg,0.003mmol), potassium tert-butoxide (36mg, 0.32mmol) and BINAP (2mg, 0.003mmol) were heated to 100 ℃ and the reaction was stirred overnight. After the reaction was checked by LC-MS to be substantially complete, water (50mL) and methylene chloride (50mL) were added to the reaction mixture. The organic phase was separated and the aqueous phase was extracted once more with dichloromethane (50 mL). The organic phases were combined and concentrated under reduced pressure and the crude product was purified by silica gel column chromatography (PE: EA ═ 2:1) to give the compound (65mg) as a yellow solid. MS M/z 664.8[ M + H ]] + 。
The third step: to the intermediate (65mg, 0.1mmol) in dichloromethane (10mL) was added trifluoroacetic acid (3mL), and the reaction was stirred at room temperature for 4 hours. Adding ammonia water to neutralize until pH is 8-9, and using dichloroMethane (30mL) was extracted three times. The combined organic phases were concentrated under reduced pressure. The crude product was purified by HPLC prep. to give the desired product as a white solid (18 mg). MS M/z 434.6[ M + H ]] + . 1 H NMR(400MHz,CD 3 OD):δ7.36(s,1H),7.50-7.42(m,3H),7.36-7.34(m,1H),5.46(m,1H),4.61-4.50(m,2H),4.53-4.35(m,2H),3.97-3.78(m,2H),3.48-3.41(m,1H),3.16-3.07(m,3H),2.92(s,6H),2.12-2.07(m,2H),1.73-1.62(m,2H),1.32-1.28(d,J=6.8Hz,6H).
Synthesized according to the procedure for example 27, starting from intermediates C or E, and different aromatic and saturated ring-substituted amines and heterocycloalkyl-substituted amines or alcohols, to give examples 28-39;
example 40: 2- (4-aminophenyl) -N- (2- (4-aminopiperidin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) -1,2,3, 4-tetrahydroisoquinolin-4-amine
The first step is as follows: intermediate A1(60.0mg, 0.093mmol) was dissolved in methanol (10mL), 4M HCl/MeOH (1mL) was added, and the mixture was stirred at room temperature for 2 h. After completion of the reaction was detected by LC-MS, water (40mL) and ethyl acetate (40mL) were added to the reaction mixture, followed by extraction with ethyl acetate (40mL) twice, and the separated organic phase was concentrated under reduced pressure and dried to give a yellow solid intermediate product (40.0 mg). LC-MS [ M + H ]] + :m/z 541.7。
The second step is that: to a solution of the above intermediate (40mg,0.074mmol) in DMF (5mL) was addedAnhydrous K 2 CO 3 (21mg,0.15mmol) and p-fluoronitrobenzene (13mg,0.092mmol), the reaction was heated to 130 ℃ overnight. After the reaction was checked by LC-MS to be substantially complete, water (30mL) and ethyl acetate (30mL) were added to the reaction mixture. The organic phase was separated and the aqueous phase was extracted once more with ethyl acetate (30 mL). The organic phases were combined and concentrated under reduced pressure and the crude product was purified by silica gel column chromatography (PE: EA ═ 2:1) to give the compound as a yellow oil (24 mg). LC-MS [ M + H ]] + :m/z 662.8。
The third step: Pd/C (10% wt,5mg) was added to a methanol solution (10mL) of the above intermediate (24mg, 0.037mmol), and the reaction mixture was stirred at room temperature for 3 hours under a hydrogen atmosphere of 1 atm. LC-MS detects the reaction is finished, and the reaction liquid is filtered by diatomite and then is concentrated under reduced pressure. After drying, the product was obtained as a white solid (14 mg). LC-MS [ M + H ]] + :m/z 498.7。 1 H NMR(400MHz,MeOD-d 4 ):δ7.66(s,1H),7.46(d,J=7.6Hz,2H),7.26-7.33(m,2H),7.02-6.88(m,3H),6.69(d,J=7.6Hz,1H),5.61-5.63(m,1H),4.97-4.92(m,2H),4.62-4.45(m,2H),3.89-3.75(m,2H),3.48-3.38(m,1H),3.07-3.00(m,3H),2.08-2.04(m,2H),1.63-1.56(m,2H),1.28(d,J=6.8Hz,6H)。
Synthesized according to the procedure of example 40, intermediate a was reacted with 2-chloro-4-trifluoromethylpyridine to give example 41;m/z:552.3[M+H] + . 1 H NMR(400MHz,CD 3 OD):δ8.27(m,1H),7.75(s,1H),7.34(s,1H),7.50-7.34(m,5H),5.46(m,1H),4.61-4.53(m,2H),4.53-4.43(m,2H),3.97-3.78(m,2H),3.48-3.40(m,1H),3.16-3.06(m,3H),2.12-2.09(m,2H),1.73-1.63(m,2H),1.32-1.29(d,J=7.2Hz,6H).
example 42: 2- (3-aminophenyl) -N- (2- (4-aminopiperidin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) -1,2,3, 4-tetrahydroisoquinolin-4-amine
The first step is as follows: n- (1,2,3, 4-tetrahydroisoquinolin-4-yl) formyl tert-butyl ester (405mg,1.63mol), 3-nitrobromobenzene (300mg,1.48mol), Pd2(dba)3(67.8mg,0.074mmol), Xantphos (70mg,0.148mmol) and cesium carbonate (1.4g,4.44mol) were dissolved in 1,4-dioxane (10mL) under nitrogen. The reaction was heated to 110 ℃ overnight. The reaction mixture was filtered through celite, the filtrate was concentrated under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 20:1) to give an intermediate compound (322mg) as a yellow oil. LC-MS [ M + H ] +: M/z 370.1.
The second step is that: the intermediate compound (322mg) was dissolved in dichloromethane (15mL), and trifluoroacetic acid (8mL) was added thereto, followed by stirring at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure to give a crude intermediate compound (250mg) as a pale black oil. LC-MS [ M + H ]] + :m/z 270.1。
The third step: the above intermediate compound (65.5mg,0.24mmol) and intermediate A (80mg,0.19mmol) were dissolved in acetonitrile (5mL) and N, N-diisopropylethylamine (72.4mg,0.56mmol) was added. The reaction was stirred at room temperature for 16 hours. The reaction solution was concentrated under reduced pressure, and the resulting crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate ═ 5:1) to give a yellow solid intermediate compound (102 mg). LC-MS [ M + H ]] + :m/z 662.2。
The fourth step: the above intermediate compound (92mg,0.13mmol) was dissolved in MeOH/THF/H 2 To a mixed solution of O (4mL/4mL/4mL), ammonium chloride (46mg,0.08mmol) and zinc powder (28.5mg,0.08mmol) were added in this order, and the mixture was stirred at room temperature for 16 hours. The reaction was checked by LC-MS to be substantially complete, and the reaction solution was poured into water (20mL) and extracted twice with ethyl acetate (30 mL). The combined organic phases were dried and concentrated under reduced pressure and the crude product purified by Prep-TLC (eluent: petroleum ether/ethyl acetate ═ 2:1) to give the intermediate compound (78mg) as a yellow solid. LC-MS [ M + H ]] + :m/z 632.3。
The fifth step: the intermediate compound (10.3mg,0.016mmol) was dissolved in ethyl acetate (1mL), Pd/C (5mg) was added, and the mixture was purged with hydrogen balloon 3 times, and stirred at room temperature overnight for 3 days. Celite filtration and washing of the filtrate with methanol, concentration of the filtrate under reduced pressure and preparative HPLC separation of the resulting crude gave example 42 as a grey solid (1.04mg)] + :m/z 498.3。 1 H NMR(400MHz,MeOD-d 4 ):δ7.66(s,1H),7.46(d,J=7.6Hz,1H),7.26-7.33(m,4H),7.02(d,J=9.6Hz,1H),6.88(s,1H),6.69(d,J=7.6Hz,1H),5.61-5.63(m,1H),4.92-4.97(m,2H),4.62(m,1H),4.45(m,1H),3.94-3.79(m,2H),3.38-3.48(m,1H),3.00-3.07(m,3H),2.04-2.08(m,2H),1.56-1.62(m,2H),1.28(d,J=6.8Hz,6H)。
Synthesized according to the procedure of example 40, intermediate a was reacted with 2-chloro-4-cyanopyrimidine to provide example 43;
m/z:510.3[M+H] + 。 1 H NMR(400MHz,CD 3 OD):δ8.15(s,2H),7.34(s,1H),7.50-7.40(m,3H),7.36-7.34(m,1H),5.46(m,1H),4.61-4.53(m,2H),4.53-4.43(m,2H),3.97-3.78(m,2H),3.48-3.40(m,1H),3.16-3.06(m,3H),2.12-2.09(m,2H),1.73-1.63(m,2H),1.32-1.29(d,J=7.2Hz,6H).
prepared according to the method of example 42, intermediate obtained by reacting tert-butyl-N- (1,2,3, 4-tetrahydroquinolin-4-yl) formyl tert-butyl ester with 3-nitrobromobenzene was reacted with intermediate A to obtain example 44;
m/z:498.3[M+H] + 。 1 H NMR(400MHz,MeOD-d 4 ):δ7.68(s,1H),7.46(m,1H),7.26-7.02(m,5H),6.88-6.69(m,2H),5.61-5.63(m,1H),4.92-4.97(m,2H),4.62(m,1H),4.45(m,1H),3.94-3.79(m,2H),3.38-3.48(m,1H),3.00-3.07(m,3H),2.04-2.08(m,2H),1.56-1.62(m,2H),1.30(d,J=6.8Hz,6H)。
example 45: n- (2- (4-aminopiperidin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) -2- (piperidin-3-yl) -1,2,3, 4-tetrahydroisoquinolin-4-amine
The first step is as follows: to a solution of intermediate A2(60mg, 0.11mmol) in 1, 2-dichloroethane (10mL) was added N-tert-butoxycarbonyl-3-piperidone (22mg,0.11mmol) and acetic acid (0.5 mL). After the reaction mixture was stirred at room temperature for 30 minutes, sodium cyanoborohydride (15mg,0.24mmol) was added to the reaction. The reaction was stirred at room temperature overnight. After completion of the reaction was checked by LC-MS, water (30mL) and methylene chloride (50mL) were added to the reaction mixture. After separation of the organic phase, the aqueous phase was extracted once more with dichloromethane (50 mL). The combined organic phases were concentrated under reduced pressure and dried to give an oily intermediate compound (51 mg).
The third step: the above compound (51mg, 0.07mmol) was dissolved in HBr/AcOH (2mL), reacted overnight, and NaOH solution (10mL) and dichloromethane (30mL) were added. The organic phase was separated and the aqueous phase was extracted twice more with dichloromethane (30 mL). The combined organic phases were concentrated under reduced pressure and the crude product isolated by HPLC prep to give a pale yellow solid (15 mg). LC-MS [ M + H ]] + :m/z 490.3。 1 H NMR(400MHz,MeOD-d 4 ):7.72(s,1H),7.49-7.44(m,1H),7.36-7.21(m,4H),5.69-5.67(m,1H),4.25-4.15(m,1H),4.06-3.95(m,1H),3.53-3.34(m,4H),3.26-3.02(m,7H),2.09-2.97(m,4H),1.96-1.92(m,1H),1.89-1.57(m,3H),1.28(d,J=6.8Hz,6H)。
Synthesized according to the procedure of example 45, intermediate a2 or an analog thereof was reacted with various commercially available aldehydes or ketones to afford examples 46-55;
example 56: (E) -N- (4- (4- ((2- (4-aminopiperidin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) amino) -3, 4-dihydroisoquinolin-2- (1H) -yl) phenyl) -4- (dimethylamino) but-2-enoyl
The first step is as follows: to a solution of intermediate A3(60mg, 0.09mmol) in ethanol (10mL) and water (5mL) were added iron powder (30mg,0.54mmol) and ammonium chloride (30mg,0.56 mmol). The reaction solution was heated to 80 ℃ and stirred for 5 hours. Detecting the reaction completion by LC-MS, filtering the reaction solution, and concentrating the filtrate under reduced pressure. The crude product was dried to give an off-white solid (51.2 mg).
The second step is that: to a solution of the above intermediate (51mg, 0.08mmol) in dichloromethane (10mL) was added (E) -3-N, N-dimethylaminomethylacryloyl chloride hydrochloride (17mg,0.09mmol) and DIEA (40mg,0.31mmol). The reaction was stirred at room temperature overnight. After completion of the reaction was detected by LC-MS, water (30mL) and ethyl diacetate (50mL) were added to the reaction mixture. After separation of the organic phase, the aqueous phase was extracted twice more with ethyl acetate (50 mL). The combined organic phases were concentrated under reduced pressure and dried to give an oily intermediate compound (52 mg).
The third step: the above compound (52mg, 0.07mmol) was dissolved in HBr/AcOH (2mL), reacted overnight, and NaOH solution (10mL) and dichloromethane (30mL) were added. The organic phase was separated and the aqueous phase was extracted twice more with dichloromethane (30 mL). The combined organic phases were concentrated under reduced pressure and the crude product isolated by HPLC prep to give a pale yellow solid (15 mg). LC-MS [ M + H ]] + :m/z 690.8。1H NMR(400MHz,MeOD-d4):δ7.67(s,1H),7.48-7.43(m,2H),7.30-7.25(m,4H),7.10(m,1H),6.81-6.89(m,2H),6.53(m,1H),5.64(m,1H),4.90-4.95(m,2H),4.57(m,1H),4.43(m,1H),3.97-3.99(m,2H),3.72-3.85(m,2H),3.36-3.49(m,2H),3.01-3.06(m,3H),2.92(s,6H),2.06-2.09(m,2H),1.54-1.66(m,2H),1.29(d,J=6.8Hz,3H).
Synthesized according to the procedure for example 56, intermediate a2 or an analog thereof was reacted with various commercially available carboxylic acids or acid chlorides to afford examples 57-63;
synthesis according to the procedures of examples 27 and 56 using intermediate D with various commercially available carboxylic acids or acid chlorides gave examples 64-66;
example 67: n- (2- (4-aminopiperidin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) -2- (4-aminopyrimidin-2-yl) -1,2,3, 4-tetrahydroisoquinolin-4-amine
The first step is as follows: under the protection of nitrogen, the compound N- (1,2,3, 4-tetrahydroisoquinolin-4-yl) formyl tert-butyl ester (400mg,1.6mol), 2-chloropyrimidin-4-amine (418mg,3.2mol), N, N-diisopropylethylamine (619.2mg,4.8mmol) was dissolved in DMF (8mL) and heated to 80 ℃ for reaction overnight. After filtration through celite, the filtrate was concentrated under reduced pressure and the resulting crude product was purified by column chromatography (eluent: petroleum ether/ethyl acetate 10:1) to give a grey solid (96 mg). LC-MS [ M + H ] +: M/z 342.1.
The second step is that: the above intermediate compound (76mg) was dissolved in methylene chloride (1.5mL), and trifluoroacetic acid (0.8mL) was added thereto and the mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure to give a crude intermediate compound (65mg) as a pale black oil. LC-MS [ M + H ]] + :m/z 242.2。
The third step: the above intermediate compound (45mg,0.18mmol) and intermediate A (65mg,0.27mmol) were dissolved in acetonitrile (5mL), and N, N-diisopropylethylamine (104mg,0.81mmol) was added, and the reaction was stirred at room temperature for 16 hours. The reaction mixture is concentrated under reduced pressure and the crude product obtained is purified by column chromatography (eluent: petroleum ether/ethyl acetate 5:1) to give greySolid intermediate compound (110 mg). LC-MS [ M + H ]] + :m/z 663.2。
The fourth step: the above intermediate compound (21mg,0.03mmol) was dissolved in acetonitrile (5mL), and trimethyliodosilane (0.5mL) was added, and the mixture was stirred at room temperature overnight. Water (30mL) was added to the reaction mixture, which was then extracted twice with ethyl acetate (30 mL). The combined organic phases were dried over anhydrous sodium sulfate, concentrated under reduced pressure and the crude product was purified by HPLC prep. to give example 67 compound as an off-white solid (5.74mg)] + :m/z 499.3。1H NMR(400MHz,MeOD-d 4 ):δ7.67(s,1H),7.65(d,J=7.2Hz,1H),7.45(d,J=7.6Hz,1H),7.40-7.37(m,1H),7.33-7.29(m,2H),6.14(d,J=7.2Hz,1H),5.69(m,1H),5.11(m,1H),4.95-4.94(m,1H),4.81(m,1H),4.57-4.54(m,1H),4.02(m,1H),3.45-3.39(m,1H),3.09-3.00(m,3H),2.11-2.05(m,2H),1.64-1.58(m,2H),1.28(d,J=6.8Hz,6H)。
Example 68: n- (2- (4-aminopiperidin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) -2- (4-aminopyridin-2-yl) -1,2,3, 4-tetrahydroisoquinolin-4-amine
The first step is as follows: under the protection of nitrogen, the compounds N- (1,2,3, 4-tetrahydroisoquinolin-4-yl) formyl tert-butyl ester (400mg,1.6mol), 2-chloro-4-nitropyridine (201.4mg,1.2mol), Pd2(dba)3(55.4mg,0.06mmol), Xantphos (57.6mg,0.12mmol) and cesium carbonate (1.2g,3.63mol) were dissolved in 1,4-dioxane (10 mL). The reaction solution was heated to 110 ℃ and reacted overnight. The reaction solution was filtered through celite, and then concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (eluent: petroleum ether/ethyl acetate 10:1) to give the intermediate product (26.5mg) as a yellow solid. LC-MS [ M + H ] +: M/z 371.1.
The second step: the above intermediate compound (26.5mg) was dissolved in dichloromethane (2mL), followed by addition of TFA (1mL), stirring at room temperature for 3 hours, and concentration under reduced pressure to give the intermediate product as a dark gray oil (21 mg). LC-MS [ M + H ]] + :m/z 271.1
The third step: the intermediate compound (21mg,0.08mmol) and intermediate A were added(33.4mg,0.08mmol) was dissolved in acetonitrile (2mL) and N, N-diisopropylethylamine (30.2mg,0.23mmol) was added and the reaction stirred at room temperature for 16 h. The reaction solution was concentrated under reduced pressure, and the resulting crude product was purified by Prep-TLC (eluent: petroleum ether/ethyl acetate 4:1) to give a yellow solid intermediate product (29 mg). LC-MS [ M + H ]] + :m/z 663.2。
The fourth step: the above intermediate compound (29mg,0.04mmol) was dissolved in MeOH/THF/H 2 To O (2mL/2mL/2mL), ammonium chloride (46mg,0.08mmol) and zinc powder (28.5mg,0.08mmol) were added in this order, and the mixture was stirred at room temperature for 16 hours. Water (8mL) was added to the reaction solution, and the mixture was extracted twice with ethyl acetate (20 mL). The combined organic phases were dried over anhydrous sodium sulfate, concentrated under reduced pressure and the crude product purified by Prep-TLC (eluent: dichloromethane/methanol-50: 1) to give the intermediate product as a white solid (20 mg). LC-MS [ M + H ]] + :m/z 633.3。
The fifth step: the above intermediate compound (5mg) was dissolved in acetonitrile (1mL), and trimethyliodosilane (0.3mL) was added thereto, followed by stirring at room temperature overnight. Water (20mL) was added to the reaction mixture, which was then extracted twice with ethyl acetate (20 mL). The combined organic phases were dried over anhydrous sodium sulfate, concentrated under reduced pressure and the crude product was purified by HPLC preparative to give the intermediate product as an off-white solid (2.02mg)]+:m/z 499.3。 1 H NMR(400MHz,MeOD-d 4 ):δ7.68(s,1H),7.52(d,J=6.8Hz,1H),7.45(d,J=7.6Hz,1H),7.40-7.30(m,3H),6.32(m,1H),6.16(m,1H),5.72-5.70(m,1H),4.82(s,1H),4.68(m,1H),4.09-4.04(m,1H),3.93-3.88(m,1H),3.43-3.37(m,1H),3.06-2.98(m,3H),2.09-2.06(m,2H),1.61-1.55(m,2H),1.33-1.27(m,8H)。
Example 69: (E) -N- (3- (4- ((2- (4-aminopiperidin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) amino) -3, 4-dihydroisoquinolin-2 (1H) -yl) phenyl) -4- (dimethylamino) but-2-enoyl
The first step is as follows: the compound (1- (4- ((2- (3-aminophenyl) -1,2,3, 4-tetrahydroisoquinolin-4-yl) amino) -8-isopropylpyrazolo [1,5, -a)][1,3,5]Triazin-2-yl) piperidin-4-yl) carbonoyl benzyl ester (64mg,0.1mmol) was dissolved in pyridine/dichloromethane (2mL/1mL) and (E) -4- (dimethylamino) but-2-enoic acid (20.2mg,0.12mmol), one drop of POCl was added 3 Stirred at room temperature for 1.5 hours, and saturated NaHCO was poured in 3 To a solution of water (20mL), ethyl acetate (20mL) was extracted three times. The combined organic phases were dried over anhydrous sodium sulfate and the filtrate was concentrated under reduced pressure. The crude product was slurried with methanol, the filter cake washed with methanol, and the combined filtrates concentrated to give a crude intermediate product (34mg) as a yellow solid. LC-MS [ M + H ]] + :m/z 743.7。
The second step is that: the above intermediate compound (29mg,0.04mmol) was dissolved in acetonitrile (1mL), and trimethyliodosilane (42.2mg,0.19mmol) was added, and the mixture was stirred at room temperature overnight. The reaction was quenched by addition of methanol, the reaction was concentrated under reduced pressure, and the crude product was purified by HPLC prep. to give example 69 (5.1mg) as a pale yellow solid. LC-MS [ M + H ] +: M/z 609.4. 1H NMR (400MHz, MeOD-d4): δ 7.67(s,1H),7.45-7.48(m,2H),7.30-7.32(m,2H),7.21-7.27(m,2H),7.10(d, J ═ 8.4Hz,1H),6.81-6.89(m,2H),6.53(m,1H),5.61-5.64(m,1H),4.90-4.95(m,2H),4.57(m,1H),4.43(m,1H),3.97-3.99(m,2H),3.72-3.85(m,2H),3.36-3.49(m,2H),3.01-3.06(m,3H),2.92(s,6H),2.06-2.09(m,2H), 1.54-6H), 1.29.54 (m, 6H), 1H, 6H).
Example 70: (E) -1- (3- (4- ((2- (4-aminopiperidin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) amino) -3, 4-dihydroisoquinolin-2 (1H) -yl) piperidin-1-yl) -4- (dimethylamino) but-2-enoyl
The first step is as follows: the intermediate compound 3- (4- ((2- (4- (((benzyloxy) carbonyl) amino) piperidin-1-yl) -8-isopropylpyrazolo [1,5, -a)][1,3,5]Triazin-4-yl) amino) -3, 4-dihydroisoquinolin-2 (1H) -yl) piperidine-1-carboxylic acid tert-butyl ester (30mg,0.04mmol) was dissolved in dichloromethane (2mL), followed by addition of TFA (1mL) and stirring at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure to give a crude intermediate compound (20mg) as a pale black oil. LC-MS [ M + H ]] + :m/z 624.3。
Second step of: the above intermediate compound (34mg,0.055mmol) was dissolved in DMF (2mL), followed by addition of (E) -4- (dimethylamino) but-2-enoic acid (9.94mg,0.06mmol), HATU (27mg,0.07mmol), DIEA (21mg,0.16mmol), and stirring at room temperature for 5 hours. Water (8mL) was added to the reaction mixture, and a solid precipitated. The precipitated solid was dried to give a crude intermediate compound (39mg) as a white solid. LC-MS [ M + H ]] + :m/z 735.5。
The third step: the above intermediate compound (39mg, 0.05mmol) was dissolved in acetonitrile (1mL), and trimethyliodosilane (0.3mL) was added thereto, followed by stirring at room temperature for 5 hours. Water (20mL) was added to the reaction mixture, which was then extracted twice with ethyl acetate (20 mL). The combined organic phases were dried over anhydrous sodium sulfate, concentrated under reduced pressure and the crude product was purified by HPLC prep. to give example 70 as a grey solid (12.9mg)] + :m/z 601.5。 1 H NMR(400MHz,MeOD-d 4 ):δ7.73(s,1H),7.46-7.34(m,4H),6.98-6.93(m,1H),6.72-6.66(m,1H),5.97-5.92(m,1H),4.90-4.91(m,1H),4.78-4.66(m,2H),4.61-4.54(m,3H),4.05-3.92(m,4H),3.76-3.63(m,1H),3.51-3.33(m,4H),3.13-2.98(m,3H),2.90(s,6H),2.35-2.31(m,1H),2.04-1.98(m,4H),1.67-1.54(m,3H),1.29(d,J=6.8Hz,6H)。
Synthesized according to the procedures of examples 69 and 70 using intermediate a3 or an analog thereof reacted with various commercially available carboxylic acids or acid chlorides to afford examples 71-73;
example 74: n- (2- (4- ((2- (4-aminopyridin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) amino) -3, 4-dihydroisoquinolin-2 (1H) -yl) piperidin-4-yl) acrylamide
The first step is as follows: the intermediate compound (1- (4- ((2- (4-aminopyridin-2-yl) -1,2,3, 4-tetrahydroisoquinolin-4-yl) amino) -8-isopropylpyrazolo [1,5, -a)][1,3,5]Triazine-2-yl)Piperidin-4-yl) formylbenzyl ester (15mg,0.02mmol), potassium phosphate (20mg,0.08mmol) in THF/H 2 To the mixed solution of O (6mL/3mL), 3-chloropropionyl chloride (4mg,0.02mmol) was added, and the reaction was carried out at room temperature for 2 hours. After dilution with water (30mL), the mixture was extracted three times with dichloromethane (30mL), and the combined organic phases were dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to give the crude intermediate product (18mg) as a grey solid.
LC-MS[M-H] - :m/z 721.4。
The second step is that: the above intermediate compound (18mg,0.02mmol) was dissolved in trifluoroacetic acid (3mL) and reacted at room temperature for 5 hours. After the reaction mixture was diluted with 30mL of water, it was extracted three times with methylene chloride (30 mL). The combined organic phases are dried over anhydrous sodium sulfate, and the filtrate is concentrated under reduced pressure to obtain a crude intermediate. The crude intermediate was dissolved in THF/H 2 To a mixed solvent of O (6mL/3mL) was added NaOH (2mg,0.04mmol), and the reaction mixture was stirred overnight at room temperature. To the above reaction solution was added water (50mL) for dilution, and extracted three times with dichloromethane (50mL), the combined organic phases were dried over anhydrous sodium sulfate, the filtrate was concentrated under reduced pressure, and the resulting crude product was prepared by HPLC to give example 74 compound (4.35mg) as a yellow solid. LC-MS [ M + H ]] + :m/z 553.3。 1 H NMR(400MHz,DMSO-d 6 ):δ8.67(s,1H),8.02(d,J=6.0Hz,1H),7.86-7.82(m,2H),7.75(s,1H),7.36-7.30(m,3H),7.26-7.22(m,1H),6.98(d,J=6.0Hz,1H),6.47-6.40(m,1H),6.33(dd,J=17.0,2.0Hz,1H),5.87(d,J=11.6Hz,1H),5.63-5.59(m,1H),4.84-4.56(m,5H),4.17-4.11(m,2H),4.03-3.92(m,2H),3.31-3.25(m,1H),3.01-2.84(m,3H),1.95-1.91(m,2H),1.55-1.35(m,2H),1.25(d,J=6.8Hz,6H)。
Example 75: n- (2- (4- ((2- (4-aminopyrimidin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) amino) -3, 4-dihydroisoquinolin-2 (1H) -yl) piperidin-4-yl) acrylamide
The first step is as follows: the intermediate compound (1- (4- ((2- (4-aminopyrimidin-2-yl) -1,2,3, 4-tetrahydroisoquinolin-4-yl) amino) -8-isopropylpyrazolo [1,5, -a)][1,3,5]Triazine-2-yl) piperidin-4-yl) carbonoyl benzyl ester (60mg,0.09mmol), triethylamine (67mg,0.66mmol) were dissolved in DCM (6mL), and 3-chloropropionyl chloride (60mg,0.47mmol) was added under cooling on an ice bath for reaction at room temperature for 2 hours. After dilution with water (20mL), the mixture was extracted three times with dichloromethane (20mL), and the combined organic phases were dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to give the crude intermediate product (68mg) as a grey solid. LC-MS [ M-H ]] - :m/z 722.5。
The second step is that: the intermediate compound (68mg,0.09mmol) was dissolved in acetonitrile (3mL), and TMSI (3drops) was added dropwise to the reaction mixture, followed by reaction at room temperature for 1 hour. The reaction was quenched by addition of methanol (3 mL). Concentrating under reduced pressure, and dissolving the crude product in THF/H 2 To a mixed solution of O (6mL/3mL), NaOH (38mg,0.94mmol) was added, and the reaction was carried out at room temperature for 5 hours. Dilute with water (50mL), extract three times with dichloromethane (50mL), dry the combined organic phases over anhydrous sodium sulfate, concentrate the filtrate under reduced pressure, and prepare the crude product by HPLC to give example 75 as a grey solid (1.6 mg). LC-MS [ M + H ]] + :m/z 554.3。 1 H NMR(400MHz,CD 3 OD):δ8.19(d,J=5.6Hz,1H),7.64(s,1H),7.48(d,J=5.6Hz,1H),7.43(d,J=7.6Hz,1H),7.34-7.25(m,3H),6.46-6.42(m,2H),5.82(dd,J=9.2,2.8Hz,1H),5.57-5.55(m,1H),5.11(d,J=17.2Hz,1H),4.97-4.86(m,3H),4.48-4.40(m,1H),4.28-4.24(m,1H),3.41-3.36(m,1H),3.06-3.00(m,3H),2.07-2.03(m,2H),1.62-1.58(m,2H),1.28(d,J=6.8Hz,6H).
Synthesized according to the procedure for example 56, intermediate a2 or an analog thereof was reacted with various commercially available carboxylic acids or acid chlorides to afford examples 76-77;
example 78: r-1- ((E) -4- (dimethylamino) but-2-enyl) piperidin-3-yl-4- ((8-isopropyl-2- (((R) -piperidin-3-yl) -oxy) pyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) amino) -3, 4-dihydroisoquinoline-2 (1H) -carbonyl
The first step is as follows: to a solution of 4-amino-3, 4-dihydroisoquinoline-2 (1H) -formylbenzyl ester (500mg,1.77mmol) and triethylamine (335mg,3.3mmol) in methylene chloride (10mL) was added intermediate B (436mg,1.8 mmol). The reaction mixture was reacted at 60 ℃ for 2 hours. After dilution with water (20mL), extraction was performed three times with dichloromethane (20mL), and the combined organic phases were dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to give the crude intermediate product (630mg) as a grey solid. LC-MS [ M-H ]] - :m/z 489.2。
The second step is that: to a solution of the above intermediate (630mg,1.29mmol) in methylene chloride (10mL) was added m-chloroperoxybenzoic acid (225mg,1.30 mmol). The reaction mixture was reacted at room temperature for 2 hours. After dilution with aqueous sodium thiosulfate (20mL), the mixture was extracted three times with dichloromethane (20mL), and the combined organic phases were dried over anhydrous sodium sulfate. The filtrate was concentrated under reduced pressure to give the crude intermediate product (330mg) as a grey solid. LC-MS [ M-H ]] - :m/z 521.2。
The third step: to the above intermediate compound (101mg,0.19mmol) in N, N-dimethylformamide (1mL) under a nitrogen blanket was added NaH (7mg,0.28 mmol). The reaction mixture was stirred at room temperature for 30 minutes. Then, (S) -3-hydroxypiperidine-1-formyl tert-butyl ester (200mg,1.0mmol) was added thereto, and the mixture was heated to 80 ℃ to react overnight. After the reaction was cooled to room temperature, water (10mL) was added and extracted twice with ethyl acetate (30 mL). The combined organic phases were dried over anhydrous sodium sulfate, concentrated under reduced pressure and the resulting crude product was isolated by HPLC prep. to give a white solid (12.4 mg). LC-MS [ M + H ]] + :m/z 642.2。
The fourth step: to a solution of the above intermediate compound (12.4mg,0.02mmol) in ethyl acetate (2mL) was added Pd/C (10mg), and after 3 balloon replacements, the mixture was stirred at room temperature overnight for 2 days. After filtration through celite, concentration under reduced pressure gave crude pale yellow solid (13 mg). LC-MS [ M + H ]] + :m/z 508.3。
The fifth step: to a solution of (S) -3-hydroxypiperidine-1-formylbenzyl ester (100mg,0.43mmol) in tetrahydrofuran (5mL) under nitrogen blanket was added triphosgene (148mg,0.50 mmol). The reaction mixture was stirred at room temperature for 30 minutes. Then adding the above intermediate compound (50mg,0.1mmol), and reacted at room temperature overnight. After water (30mL) was added, the mixture was extracted with ethyl acetate (50 mL). The separated organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure and the resulting crude product was isolated by HPLC prep. to give a white solid (40 mg). LC-MS [ M + H ]] + :m/z 769.4。
And a sixth step: to a solution of the above intermediate compound (40mg,0.05mmol) in ethyl acetate (5mL) was added Pd/C (10mg), and the mixture was purged with hydrogen balloon 3 times, followed by stirring overnight at room temperature for 2 days. After filtration through celite, concentration under reduced pressure gave crude product as a pale yellow solid (20 mg). LC-MS [ M + H ]] + :m/z 635.4。
The seventh step: the above intermediate compound (20mg,0.03mmol) was dissolved in DMF (2mL), and (E) -4- (dimethylamino) but-2-enoic acid (6mg,0.04mmol), HATU (16mg,0.04mmol) and DIEA (21mg,0.16mmol) were added in this order and stirred at room temperature for 5 hours. Water (8mL) was added to the reaction mixture, and a solid precipitated. The precipitated solid was dried to give a crude intermediate compound (20mg) as a white solid. LC-MS [ M + H ]] + :m/z 746.4。
Eighth step: the above intermediate compound (20mg,0.03mmol) was dissolved in acetonitrile (1mL), and trimethyliodosilane (0.3mL) was added thereto, followed by stirring at room temperature for 5 hours. After water (20mL) was added to the reaction mixture, the mixture was extracted twice with ethyl acetate (20 mL). The combined organic phases were dried over anhydrous sodium sulfate, concentrated under reduced pressure and the crude product was purified by HPLC prep. to give example 78 compound (5mg) as a grey solid] + :m/z 646.2。 1 H NMR(400MHz,MeOD-d 4 ):δ7.81-7.85(m,1H),7.28-7.39(m,4H),6.59-6.79(m,2H),5.47-5.56(m,2H),3.43-3.87(m,12H),3.05-3.29(m,3H),2.83-2.87(m,6H),1.86-2.18(m,6H),1.30-1.31(m,2H),1.20-1.29(m,7H)。
Synthesized according to the procedure for example 78, intermediate a2 or an analog thereof was reacted with various commercially available carboxylic acids or acid chlorides to afford examples 79-63;
examples 82 and 83: (R, E) -1- (4- ((2- (4-aminopiperidin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) amino) -3, 4-dihydroisoquinolin-2 (1H) -yl) -4- (dimethylamino) but-2-enoyl and (S, E) -1- (4- ((2- (4-aminopiperidin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) amino) -3, 4-dihydroisoquinolin-2 (1H) -yl) -4- (dimethylamino) but-2-enoyl.
The first step is as follows: intermediate A2(130mg) was isolated by SFC chiral preparation to give intermediates P1(61mg) and P2(52 mg).
The preparation conditions are as follows: a separation column (OD,250 × 25mm10 μm); gradient (mobile phase: A: SupercriticalcO) 2 B EtOH (+ 0.1% 7.0mol/l AmmoniinMeOH), A: B ═ 60:40, 5min, flow 100 g/min). The retention times (Rt) of P1 and P2 on the preparative column were (Rt ═ 7.551min, P1) and (Rt ═ 6.741min, P2), respectively.
The analysis conditions are as follows: analytical column (OD-H, 250 × 4.6mm,5 μm); gradient (mobile phase: A: SupercriticalcO) 2 B is EtOH (0.1% DEA), A is 60:40, 10min, flow rate 3.0 mL/min); column temperature: 35 ℃; detection wavelength: 214 nM.
In the second step, intermediate compound P1(61.0mg,0.11mol) and (E) -4- (dimethylamino) but-2-enoic acid (20.0mg,0.12mol) were dissolved in anhydrous DMF (3.0mL) and HATU (54.0mg,0.14mol) and DIPEA (43.0mg,0.33mol) were added. The reaction was stirred at room temperature for 4 hours under nitrogen. After completion of the reaction was checked by LCMS, water (8mL) and saturated aqueous sodium carbonate (2mL) were added and a white solid precipitated which was filtered off and washed with water and the filter cake was dried to give the white intermediate product P1-1(56 mg). LC-MS [ M + H ]] + :m/z 652.4。
Referring to the above synthetic procedure for P1-1, the intermediate product P2-1(50mg) was obtained as a white solid.
In the third step, compound P1-1(56.0mg,0.09mmol) was dissolved in acetonitrile (3mL), and trimethylsilyl iodide (0.3mL) was added and the mixture was stirred at room temperature for 2 hours under nitrogen. After the reaction was completed, the reaction was concentrated by LCMS, and then concentrated by adding 10mL of methanol, and this was repeated three times. The concentrated crude product was purified by HPLC prep to give example 82 compound (17.8mg) as a white solid. LC-MS [ M + H ]] + :m/z 518.3。 1 H NMR(400MHz,MeOD-d 4 ):7.66(d,J=6.4Hz,1H),7.45-7.26(m,4H),7.07(d,J=14.8Hz,0.5H),6.84(d,J=15.2Hz,0.5H),6.70-6.57(m,1H),5.52-5.47(m,1H),5.33(d,J=17.6Hz,0.5H),5.07(d,J=16.4Hz,0.5H),4.95-4.88(m,2H),4.83-4.82(m,0.5H),4.63-4.53(m,1H),4.40(dd,J=14.0Hz,4.0Hz,0.5H),3.97-3.90(m,1.5H),3.82-3.73(m,1H),3.55-3.39(m,0.5H),3.38-3.31(m,1H),3.08-3.00(m,3H),2.90(s,3H),2.72(s,3H),2.09-2.07(m,2H),1.66-1.54(m,2H),1.30-1.27(m,6H)。
Referring to the synthesis of the compound of example 82, a white solid, the compound of example 83 (15.6mg) was obtained. LC-MS [ M + H ]] + :m/z 518.3。 1 H NMR(400MHz,MeOD-d 4 ):7.66(d,J=4.8Hz,1H),7.44-7.25(m,4H),7.08(d,J=15.2Hz,0.5H),6.87(d,J=15.2Hz,0.5H),6.71-6.57(m,1H),5.52-5.47(m,1H),5.33(d,J=17.6Hz,0.5H),5.07(d,J=17.8Hz,0.5H),4.94-4.80(m,2H),4.85-4.83(m,0.5H),4.60-4.53(m,1H),4.41(dd,J=14.0Hz,3.6Hz,0.5H),3.97-3.94(m,1.5H),3.85-3.74(m,1H),3.56-3.39(m,0.5H),3.38-3.31(m,1H),3.09-2.91(m,3H),2.90(s,3H),2.72(s,3H),2.10-2.07(m,2H),1.68-1.56(m,2H),1.30-1.27(m,6H)。
By following the procedure of examples 74, 78, 82 and 83, intermediate a2 or an analog thereof was reacted with various commercially available carboxylic acids or acid chlorides to afford examples 84-93;
example 94: 1- ((2- (4-aminopiperidin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) amino) -2, 3-dihydro-1H-indene-5-carbonitrile
The first step is as follows: intermediate A (50mg,0.11mmol), 5-bromo-2, 3-dihydro-1H-inden-1-amine (42mg,0.2mmol), DIEA (78mg,0.6mmol) was dissolved in acetonitrile (5mL) under nitrogen and reacted at 70 ℃ for 4H. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (PE: EA ═ 2:1) to give a yellow solid intermediate product (84 mg). LC-MS [ M + H ]] + :m/z 604.2。
The second step is that: to the above intermediate (84mg,0.14mmol) and zinc cyanide (25mg,0.21mmol) in N, N-dimethylformamide (10mL) was added tetrakistriphenylphosphine palladium (24mg,0.02mmol) under nitrogen. The reaction mixture was heated to 110 ℃ for 10 hours. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (PE: EA ═ 2:1) to give a white solid intermediate product (50 mg). LC-MS [ M + H ]] + :m/z 551.2。
The third step: to a solution of the above intermediate compound (50mg,0.09mmol) in acetonitrile (3mL) under nitrogen, was added trimethyliodosilane (0.5 mL). Stirred at room temperature for 2 hours. After the reaction was completed by LCMS detection, it was concentrated under reduced pressure, then concentrated again by adding 10mL of methanol, and this was repeated three times. Purification of the concentrated crude by HPLC prep. gave example 94 as a white solid (24 mg). LC-MS [ M + H ]] + :m/z 417.6. 1 H NMR(400MHz,MeOD-d 4 ):8.54(s,1H),7.68(s,1H),7.65(s,1H),7.54(d,J=7.6Hz,1H),7.45(d,J=8.0Hz,1H),5.77(t,J=8.4Hz,1H),4.78-4.72(m,2H),3.31-3.30(m,1H),3.24-3.19(m,1H),3.12-3.05(m,4H),2.90-2.65(m,1H),2.30-2.20(m,1H),1.98-1.94(m,2H),1.54-1.41(m,2H),1.29(d,J=6.8Hz,6H).
Example 95: (3- ((2- (4-aminopiperidin-1-yl) -8-isopropylpyrazolo [1,5, -a ] [1,3,5] triazin-4-yl) amino) -2, 3-dihydro-1H-inden-4-yl) dimethylphosphoryl oxide
The first step is as follows: intermediate A (30mg,0.10mmol), 5-bromo-2, 3-dihydro-1H-inden-1-amine (42mg,0.20mmol), DIEA (78mg,0.6mmol) were dissolved in acetonitrile (5mL) under nitrogen and reacted at 70 ℃ for 4H. The reaction mixture was concentrated under reduced pressure, and the crude product was purified by silica gel column chromatography (PE: EA ═ 2:1) to give a yellow solid intermediate product (34 mg). LC-MS [ M + H ]] + :m/z 602.2。
The second step is that: to a solution of the above intermediate compound (34mg,0.06mmol) in acetonitrile (3mL) under nitrogen, was added trimethyliodosilane (0.5 mL). Stirred at room temperature for 2 hours. Upon completion of the LCMS detection reaction, concentrated under reduced pressure and the crude product purified by HPLC prep. to give example 95 compound (5mg) as a white solid. LC-MS [ M + H ]] + :m/z 468.5. 1 H NMR(400MHz,CDCl 3 ):7.50(s,1H),7.41(m,1H),7.35-7.32(m,2H),6.38(m,1H),5.96(m,1H),4.81-4.72(m,2H),3.26-2.97(m,4H),2.84-2.75(m,4H),2.39(m,2H),2.30(m,2H),2.12(m,2H),1.76-1.68(m,6H),1.20(m,6H).
Synthesized according to the methods of examples 94, 95 using intermediate a2 or an analog thereof reacted with various commercially available carboxylic acids or acid chlorides to afford examples 96-98;
test example 1 enzyme Activity test
The compounds of the examples were tested for their inhibition on CDK7/CycH/MAT1(Carna) and CDK9/CycT1(Carna) kinases, with PHA-793887 and Dinaciciclib as positive control compounds. The activity test of the compounds of the examples was performed on 2 kinases using the method of Mobility shift assay.
The specific operation flow is as follows: (1) preparing 1 XKinase buffer; (2) preparation of compound concentration gradient: test compounds were tested starting at 10000nM concentration, diluted 100-fold final concentration in 100% DMSO solution in 384source plates, 3-fold compound dilution, 10 concentrations. Using a dispenser Echo 550 to the target plate 384-well-plate to transfer 250nL 100 times the final concentration of the compound. A2.5 fold final concentration of Kinase solution was prepared using a1 XKinase buffer. (3) Add 10. mu.L of 2.5 fold final concentration kinase solution to the compound well and positive control well, respectively; mu.L of 1 × Kinase buffer was added to the negative control wells. (4) Centrifuge at 1000rpm for 30 seconds, shake the plate and incubate at room temperature for 10 minutes. (5) A mixture of ATP and Kinase substrate at 5/3 fold final concentration was made up using 1 XKinase buffer. (6) The reaction was initiated by adding 15. mu.l of a mixed solution of ATP and substrate at 5/3 fold final concentration. (7) The 384 well plates were centrifuged at 1000rpm for 30 seconds, shaken and mixed and incubated at room temperature for the appropriate time. (8) Add 30. mu.l of termination detection solution to stop the kinase reaction, centrifuge at 1000rpm for 30 seconds, and mix by shaking. (9) The conversion was read using a Caliper EZ Reader. (10) The formula% Inhibition ═ Conversion% max -Conversion%_ sample/ Conversion%_ max -Conversion%_ min X 100, wherein: conversion% \ u sample Is the conversion reading for the sample; conversion% \ u min Is the mean of the negative control wells, representing conversion readings without enzyme live wells; conversion% \ u max Is the mean of the positive control wells and represents the conversion reading for wells without compound inhibition. The dose-response curves were fitted using the log values of the concentrations as the X-axis and the percent inhibition as the Y-axis, using the analysis software GraphPad Prism 5 log (inhibitor) vs. response-Variable slope, to obtain the IC50 values of each compound for enzyme activity. The calculation formula is Y ═ Bottom + (Top-Bottom)/(1+10^ ((LogIC) 50 -X)*Hill Slope))。
As a result: most of the compounds of the examples of the invention have high CDK7 kinase inhibitory activity, and still show high inhibitory activity (the inhibitory rate is more than 60%) at the concentration as low as 100 nM; and most of the compounds of the examples had weak inhibitory activity against CDK9, and still showed a better inhibition at 1000nM concentrationLow inhibitory activity (inhibition less than 50%). Most of the example compounds showed higher CDK7/CDK9 kinase selectivity. (wherein the inhibition rate is ++++ > or more than 80%; 80%<+++≤60%;60%<++≤30%;+<30%;IC 50 Represents A is less than or equal to 20 nM; 20nM<B≤100nM;100nM<C≤1000nM;D>1000nM。)
All documents referred to herein are incorporated by reference into this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.
Claims (10)
1. An amino-substituted aromatic heterocyclic pyrazole compound shown as a general formula I, or pharmaceutically acceptable salt thereof, or enantiomer, diastereomer, tautomer, torsional isomer, solvate, polymorph or prodrug thereof,
in the formula:
w is selected from CR w Or N; r w Independently selected from H, halogen, cyano, C1-C6 alkyl or haloalkyl;
R 1 independently selected from C1-C10 alkyl or haloalkyl, 3-10 membered cycloalkyl or heterocycloalkyl, C1-C10 alkoxy or haloalkoxy, 3-10 membered cycloalkyl ether or heterocycloalkyl ether, C1-C10 alkyl or haloalkyl substituted amino, 3-10 membered cycloalkyl or heterocycloalkyl substituted amino; and the above alkyl, cycloalkyl, heterocycloalkyl may be substituted with one or several substituents selected from the group consisting of: halogen, deuterium, hydroxyl, substituted or unsubstituted amino, C1-C6 alkyl, hydroxyl-substituted C1-C6 alkyl, amino-substituted C1-C6 alkyl, C1-C6 alkoxy, 3-10 membered cycloalkyl or heterocycloalkyl-substituted C1-C6 alkyl;
R 2 independently selected from C1-C10 alkyl or haloalkyl, 3-10 membered cycloalkyl or heterocycloalkyl;
R a selected from hydrogen, deuterium, halogen, C1-C6 alkyl or haloalkyl, 3-to 10-membered cycloalkyl or heterocycloalkyl;
R b 、R c 、R d 、R e each independently selected from hydrogen, deuterium, halogen, C1-C6 alkyl or haloalkyl, 3-to 10-membered cycloalkyl or heterocycloalkyl, or R b And R c 、R d And R e Form a C ═ O bond or a 3-6 membered carbocyclic or heterocyclic ring, respectively;
m and n are respectively and independently selected from integers of 0-3;
cy is selected from 3-10 membered cycloalkyl or heterocycloalkyl, 5-12 membered monocyclic or fused aromatic or heteroaromatic group;
R 3 selected from the group consisting of hydrogen, deuterium, halogen, C1-C10 alkyl or haloalkyl, 3-10 membered cycloalkyl or heterocycloalkyl, 5-12 membered aryl or heteroaryl, substituted or unsubstituted amino, hydroxyl, C1-C10 alkoxy or haloalkoxy, cyano, substituted or unsubstituted amido, substituted or unsubstituted sulfonamide, substituted or unsubstituted ureido, substituted or unsubstituted sulfonylureido, substituted or unsubstituted carbamoyl, substituted or unsubstituted phosphoryl, substituted or unsubstituted alkylphosphite, substituted or unsubstitutedSubstituted alkylsilyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acryloyl, substituted or unsubstituted propioylyl, haloacetyl or haloethylsulfonyl;
y is selected from N or CRy, Ry is independently selected from hydrogen, deuterium, halogen, hydroxy, amino, cyano, C1-C6 alkyl or haloalkyl, 3-10 membered cycloalkyl or heterocycloalkyl;
R 4 independently selected from hydrogen, deuterium, halogen, C1-C10 alkyl or haloalkyl, 3-10 membered cycloalkyl or heterocycloalkyl, 5-12 membered aryl or heteroaryl, substituted or unsubstituted amino, hydroxyl, C1-C10 alkoxy or haloalkoxy, cyano, substituted or unsubstituted amido, substituted or unsubstituted sulfonamide, substituted or unsubstituted ureido, substituted or unsubstituted sulfonylureido, substituted or unsubstituted carbamoyl, substituted or unsubstituted phosphoryl, substituted or unsubstituted alkylphosphioxy, substituted or unsubstituted alkylsilyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted acryloyl, substituted or unsubstituted propioyl, haloacetyl or haloethylsulfonyl
The above-mentioned substituted or unsubstituted substituents are each independently selected from the group consisting of: including but not limited to deuterium, halogen, hydroxy, monoalkylamino, dialkylamino, C1-C6 alkyl or haloalkyl, 3-10 membered cycloalkyl or heterocycloalkyl, cyano, C1-C6 alkoxy or haloalkoxy; wherein said heteroaryl group contains 1 to 3 heteroatoms selected from the group consisting of: n, O, P or S, the heterocycloalkyl group containing 1 to 3 heteroatoms selected from the group consisting of: n, O, P or S, said ring system including spiro, bridged, fused, etc. saturated or partially unsaturated ring systems.
2. The compound according to claim 1, which is preferably a compound of formula (II), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsiomer, solvate, polymorph or prodrug thereof:
wherein R is 1 、R 2 、R 3 、R 4 、R a 、R b 、R c 、R d 、R e Cy, W, m, n are as defined in claim 1.
3. The compound of claim 1, which is preferably a compound of formula (III), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsiomer, solvate, polymorph or prodrug thereof:
wherein R is 1 、R 2 、R 3 、R 4 、R a 、R b 、R c 、R d 、R e Cy, W, m and n are defined as in claim 1.
4. A compound as claimed in claim 1, which is preferably a compound of general formula (IV), or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsionade, solvate, polymorph or prodrug thereof:
wherein Cy1 is selected from 5-10 membered aryl or heteroaryl, Cy2 is selected from 3-12 membered saturated carbocyclic or heterocyclic groups, and the range of other groups is as defined in claim 1.
5. The compound according to any one of claims 1 to 4, which is preferably a compound of general formula V, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsiomer, solvate, polymorph or prodrug thereof:
R 1 preferably C1-C6 alkyl, such as methyl; substituted or unsubstituted 5-6 membered saturated ring such as cyclohexyl, piperidinyl, piperazinyl, morpholinyl, tetrahydropyranyl and the like; substituted or unsubstituted 5-6 membered saturated cyclic group ethers such as cyclohexyl ether, piperidinyl ether, tetrahydropyranyl ether; substituted or unsubstituted 5-6 membered saturated cyclic amines, such as cyclohexylamino, piperidinamino, tetrahydropyrylamino; substituted or unsubstituted 5-6 membered saturated cyclic alkylene ethers such as piperidylmethylene ether; substituted or unsubstituted 5-6 membered saturated cyclylalkyleneamine, such as piperidinylidenemethylamine; the substituent is preferably selected from deuterium, halogen, amino, hydroxyl, dimethylamino, methoxy, hydroxymethyl, aminomethyl and the like; r 3 、R 4 The ranges W, m and n are as defined in any one of claims 1-4.
6. The compound of claim 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsiomer, solvate, polymorph, or prodrug thereof, wherein:
R 1 independently selected from C1-C6 alkyl, C1-C6 haloalkyl, 3-8 membered cycloalkyl, 3-8 membered heterocycloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, 5-8 membered heterocycloalkyl-O-, C1-C6 alkyl substituted amino, C1-C6 haloalkyl substituted amino, 3-8 membered cycloalkyl substituted amino, 3-8 membered heterocycloalkyl substituted amino; the R is 1 1 or more hydrogen atoms above may be optionally substituted with: halogen, hydroxyl, amino, cyano, single C1-C3 alkylamino, double C1-C3 alkylamino, C1-C3 alkyl, hydroxyl-substituted C1-C3 alkyl, amino-substituted C1-C3 alkyl, C1-C3 alkoxy, 3-8 membered cycloalkyl C1-C3 alkyl-, 3-8 membered heterocycloalkyl-C1-C3 alkyl-, 3-8 membered cycloalkyl, 3-8 membered heterocychcA cycloalkyl group;
or, R 2 Independently selected from C1-C6 alkyl, C1-C6 haloalkyl, 3-8 membered cycloalkyl or 3-8 membered heterocycloalkyl;
or Cy is selected from 5-8 membered cycloalkyl, 5-8 membered heterocycloalkyl, 6-10 membered monocyclic or fused aromatic group, 5-10 membered monocyclic or fused heteroaromatic group;
or, R 3 Selected from hydrogen, deuterium, halogen, hydroxyl, cyano, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkyl, C1-C6 haloalkyl, 3-6 membered cycloalkyl or heterocycloalkyl, 6-10 membered aryl, 5-8 membered heteroaryl, substituted or unsubstituted amino, substituted or unsubstituted amido, substituted or unsubstituted phosphoryl;
or, R 4 Independently selected from hydrogen, deuterium, halogen, hydroxy, cyano, C1-C6 alkyl, C1-C6 haloalkyl, 3-6 membered cycloalkyl, 3-6 membered heterocycloalkyl, 6-10 membered aryl, 5-8 membered heteroaryl, C1-C6 alkoxy, C1-C6 haloalkoxy, 3-6 membered cycloalkyl-C (O) -, 3-6 membered heterocycloalkyl-C (O) -, 3-6 membered cycloalkyl-O-C (O) -, 3-6 membered heterocycloalkyl-O-C (O) -, 6-10 membered aryl-C (O) -, 5-8 membered heteroaryl-C (O) -; said R is 4 Optionally substituted by R 41 Substituted, said R 41 Independently selected from: halogen, hydroxy, cyano, mono-C1-C6 alkylamino, di-C1-C6 alkylamino, C1-C6 alkyl, C1-C6 haloalkyl, 3-6 membered cycloalkyl or heterocycloalkyl, C1-C6 alkoxy or haloalkoxy, C2-C6 alkenyl-C (O) -; the R is 41 May be further substituted with: halogen, hydroxy, cyano, mono-C1-C6 alkylamino, di-C1-C6 alkylamino.
7. The compound of claim 1, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsiomer, solvate, polymorph, or prodrug thereof, wherein:
R 1 is composed of
Or, R 2 Is methyl or isopropyl;
9. use of a compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsomer, solvate, polymorph or prodrug thereof, for the manufacture of a medicament for the prevention, treatment, or alleviation of a disorder or a disease mediated by abnormal activity of a CDK kinase, particularly CDK7 kinase, including cancer (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, inflammatory diseases, autoinflammatory diseases, autoimmune diseases, or infectious diseases; the autoimmune disease is independently selected from rheumatoid arthritis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, hemolytic anemia, or psoriasis; the inflammatory disease is independently selected from osteoarthritis, gouty arthritis, ulcerative colitis, inflammatory bowel disease and/or the like; the infectious disease is independently selected from sepsis, septic shock, endotoxic shock, gram-negative sepsis, and/or toxic shock syndrome.
10. A pharmaceutical composition comprising a compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, torsiomer, solvate, polymorph or prodrug thereof, wherein the pharmaceutical composition comprises:
(i) an effective amount of a compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, or an enantiomer, diastereomer, tautomer, solvate, polymorph, or prodrug thereof; and
(ii) a pharmaceutically acceptable carrier.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110058977 | 2021-01-17 | ||
CN2021100589779 | 2021-01-17 | ||
CN202110185488X | 2021-02-10 | ||
CN202110185488 | 2021-02-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114805361A true CN114805361A (en) | 2022-07-29 |
CN114805361B CN114805361B (en) | 2024-02-20 |
Family
ID=82527479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210051634.4A Active CN114805361B (en) | 2021-01-17 | 2022-01-17 | Amino substituted aromatic heterocyclic pyrazole compound, preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114805361B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114213417A (en) * | 2021-11-16 | 2022-03-22 | 郑州大学 | Pyrazolo six-membered nitrogen heterocyclic compound and synthesis method and application thereof |
WO2024174949A1 (en) * | 2023-02-20 | 2024-08-29 | 江苏正大丰海制药有限公司 | Heteroaromatic ring compound serving as cdk7 kinase inhibitor, preparation thereof, and use thereof |
WO2024175024A1 (en) * | 2023-02-21 | 2024-08-29 | 杭州德睿智药科技有限公司 | New fused heterocyclic compound as cdks inhibitor and use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008130570A1 (en) * | 2007-04-20 | 2008-10-30 | Schering Corporation | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
CN110831600A (en) * | 2017-04-21 | 2020-02-21 | 金恩医疗公司 | Indole AHR inhibitors and uses thereof |
WO2020081636A1 (en) * | 2018-10-16 | 2020-04-23 | Ikena Oncology, Inc. | Indole ahr inhibitors and uses thereof |
-
2022
- 2022-01-17 CN CN202210051634.4A patent/CN114805361B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008130570A1 (en) * | 2007-04-20 | 2008-10-30 | Schering Corporation | Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
CN110831600A (en) * | 2017-04-21 | 2020-02-21 | 金恩医疗公司 | Indole AHR inhibitors and uses thereof |
WO2020081636A1 (en) * | 2018-10-16 | 2020-04-23 | Ikena Oncology, Inc. | Indole ahr inhibitors and uses thereof |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114213417A (en) * | 2021-11-16 | 2022-03-22 | 郑州大学 | Pyrazolo six-membered nitrogen heterocyclic compound and synthesis method and application thereof |
WO2024174949A1 (en) * | 2023-02-20 | 2024-08-29 | 江苏正大丰海制药有限公司 | Heteroaromatic ring compound serving as cdk7 kinase inhibitor, preparation thereof, and use thereof |
WO2024175024A1 (en) * | 2023-02-21 | 2024-08-29 | 杭州德睿智药科技有限公司 | New fused heterocyclic compound as cdks inhibitor and use thereof |
Also Published As
Publication number | Publication date |
---|---|
CN114805361B (en) | 2024-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110156786B (en) | Pyrimido-cyclic compounds, process for their preparation and their use | |
CN112142735B (en) | Condensed cyanopyridine compound, preparation method and application | |
ES2866152T3 (en) | Tyrosine amide derivatives as Rho-kinase inhibitors | |
CN111153901A (en) | Nitrogen-containing fused heterocyclic SHP2 inhibitor compound, preparation method and application | |
CN114173803A (en) | Dosage forms and regimens for amino acid compounds | |
CN112135612A (en) | Amino acid compounds and methods of use | |
CN114805361A (en) | Amino-substituted aromatic heterocyclic pyrazole compounds, preparation method and application | |
CN112457326B (en) | Aromatic heterocyclic lactam compound, preparation method and application | |
WO2020035049A1 (en) | Degradation agents for cyclin dependent kinase, preparation method therefor, pharmaceutical composition thereof and use thereof | |
CN112094269B (en) | Saturated six-membered ring heterocyclic compound, preparation method and application | |
BR112021011147A2 (en) | PYRAZOLYL-AMINO-PYRIMIDINIL DERIVATIVES BENZAMIDES AND COMPOSITIONS AND METHODS THEREOF | |
CN111936144B (en) | JAK inhibitors | |
CN114685487A (en) | Pyrimidine heterocyclic compound, preparation method and application | |
WO2016192630A1 (en) | Compound having kinase inhibiting activity, method of preparing same, and use of same | |
CN114249712A (en) | Pyrimidinyl derivatives, method for the production thereof and use thereof | |
CN112300196A (en) | Piperidine condensed ring compound, preparation method and application | |
CN110655520A (en) | Pyrimido-cyclic compounds, process for their preparation and their use | |
CN113527299A (en) | Nitrogen-containing condensed ring compounds, preparation method and application | |
CN114524810A (en) | Pyrimidine heterocyclic compound, preparation method and application | |
CN109790160B (en) | Pyrido five-membered aromatic ring compound, preparation method and application thereof | |
CN112778336B (en) | Nitrogen-containing condensed ring STING regulator compound, preparation method and application | |
CN112300173B (en) | Nitrogen-containing polycyclic compounds, preparation method and application | |
CN111057048B (en) | Aminopyrazine/pyridine compound, preparation method and application | |
CN114728932A (en) | Polyarylates as EGFR kinase inhibitors | |
WO2023169438A1 (en) | Nitrogen-containing heterocyclic cell cycle inhibitor compounds as well as preparation method therefor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |